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Abstract 
 
 Volumetric muscle loss (VML) is an injury to skeletal muscle characterized by a loss of 
more than 20% of a muscles volume. The combination of the bulk loss of tissue, transection and 
separation of myofibers proximal and distal to the injury, loss of innervation and blood supply, 
and the depletion of muscle progenitor cells results in permanent fibrosis and functional deficits 
due to loss of contractile tissue. Scaffolds, cells, and engineered constructs have been explored as 
potential therapeutic interventions to induce myogenesis at the site of a VML injury in animal 
models, in addition to limited clinical trials. This dissertation summarizes the current state of the 
field and explores possible strategies for repairing VML and understanding the mechanisms 
underlying the regenerative response of VML-damaged muscle. The challenges currently facing 
the skeletal muscle tissue engineering are presented along with potential approaches to further 
the field and deliver effective treatment options for patients and their physicians. 
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Chapter 1 
 
Introduction 
A. Overview of Skeletal Muscle Tissue 
 
Skeletal muscle, which makes up almost half of the mass of the human body, is an 
organized tissue composed of muscle cells, nerves, blood vessels and connective tissue.(Lieber 
& Friden, 2000) Cells within skeletal muscle tissue include the multi-nucleated myofibers, 
regenerative satellite cells, and fibroblasts. Skeletal muscle tissue also contains the neurons, 
endothelial cells, and smooth muscle cells associated with the nerves and blood vessels that 
respectively innervate and exchange required molecules. The primary function of skeletal muscle 
is to provide contractile force to enable locomotion at the joints. The contractile cells of skeletal 
muscle are multinucleated myofibers that contract in response to acetylcholine being released 
into the neuromuscular junction between the muscle and a motor nerve.(Lieber & Friden, 2000) 
Muscle contraction causes muscle to have very high energy demands compared to most other 
tissues in the body and requires muscle to have an extensive blood supply. Muscle cells have 
such high oxygen requirements that they contain an intracellular protein, myoglobin, which has a 
higher affinity for oxygen than hemoglobin within red blood cells.(Wittenberg, 1970)  
Skeletal muscle has a hierarchical construction in which myofibers are enclosed within a 
layer of connective tissue called endomysium and multiple endomysium-wrapped myofibers are 
surrounded by connective tissue, perimysium, to make up a structure called a fascicle.(Lieber & 
Friden, 2000) Multiple fascicles are then surrounded by a final layer of connective tissue known 
as the epimysium. The connective tissue within the muscle transmits the contractile force 
1 
 
collectively to musclulotendinous junctions after which the force is then transferred from the 
tendon to bone to provide movement.(Lieber & Friden, 2000) Within this paper and unless 
otherwise noted, the epimysium, perimysium, and endomysium, in addition to the basement 
membrane, will be collectively referred to as the extracellular matrix (ECM).  
The ECM of muscle provides a scaffold for cell attachment with specific architecture, a 
conduit for blood vessels and nerves within the belly of the muscle, and also protects myofibers 
from excessive stretching and distributes forces to minimize damage.(Gillies & Lieber, 2011) In 
addition, the ECM provides feedback from stretch and contraction to cells; mechanical stimuli 
has been shown to be very important for cell survival, growth, and metabolic activity.(KJÆR, 
2004) Fibroblasts within muscle tissue are responsible for maintaining ECM and responding to 
injury when the structure of ECM is compromised. In cases when recovery from a traumatic 
defect is incomplete, fibroblasts will deposit an excess of ECM to create a fibrotic, non-
contractile region.(Mann et al., 2011; Serrano & Muñoz-Cánoves, 2010; Tomasek, Gabbiani, 
Hinz, Chaponnier, & Brown, 2002)  
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B. Repair and Regeneration of Skeletal Muscle 
  
 When muscle receives an injury, cells within the muscle are capable of repairing and 
regenerating the contractile myofibers as well as the underlying ECM supporting 
structure.(Huard, Li, & Fu, 2002; Turner & Badylak, 2012) The normal repair process can be 
broken down into five stages: degradation, inflammation, regeneration, remodeling, and 
maturation. These stages are demarcated by the expression of different cytokines, release of 
growth factors, and the recruitment and activity of various cells. The initial degradation of 
myofibers has been linked to damage to the sarcolemma, the cell membrane of the 
myofiber.(Clarke & Feeback, 1996; Fredsted, Gissel, Madsen, & Clausen, 2007; Kasper, 1995) 
A damaged sarcolemma, which normally maintains a calcium ion gradient across the membrane, 
will allow an unregulated flood of calcium ions into the myofiber. These calcium ions activate 
proteases that will breakdown cellular components which recruit neutrophils, macrophages, and 
cells responsible for restoring the architecture of the muscle.(Fredsted et al., 2007) Necrotic 
tissue and damaged ECM also contribute to the pro-inflammatory environment present 
immediately after muscle damage.(Laumonier & Menetrey, 2016) Neutrophils are the first cells 
to arrive at the site of injury by releasing cytokines (TNF-α, IL-6), chemokines (CCL17, CCL2) 
and growth factors (FGF, HGF, IGF-I, VEGF; TGF-β1).(Laumonier & Menetrey, 2016; Tidball, 
1995; Toumi & Best, 2003) Neutrophils can also damage healthy muscle cells. Damaging 
healthy muscle cells can increase the inflammatory response by recruiting more M1 
macrophages. M1 macrophages appear hours after a muscle is injured and their numbers are 
gradually reduced over the days that follow in the case of mild injury where complete 
regeneration is possible.(Arnold et al., 2007) M1 macrophages are pro-inflammatory cells which 
lyse cells, phagocytize cellular components, and upregulate the differentiation of myoblasts from 
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satellite cells. The initial wave of M1 macrophages subsides and M2 macrophages arrive at the 
injury site 2-4 days after the initial damage. M2 macrophages suppress the inflammatory 
response and stimulate the fusion of myoblasts which forms the myofibers.(Tidball & Wehling‐
Henricks, 2007) The interplay of M1 and M2 macrophages can lead muscle repair toward 
myogenesis or fibrosis depending on injury severity and the inflammatory environment.(Muñoz-
Cánoves & Serrano, 2015) When muscle repair is deviated toward myogenesis, macrophage 
incursion into the defect site will be transient. As the inflammatory stages are taking place, 
regenerative processes will begin after having been initiated by immune cells that took part in 
clearing damaged tissue components.(Arnold et al., 2007)  
Satellite cells are key cells of the regenerative stage. Satellite cells differentiate in 
response to factors released by the ECM upon incurring damage.(Montarras, L'honoré, & 
Buckingham, 2013) Factors that have been shown to activate satellite cells include: 
FGF(DiMario, Buffinger, Yamada, & Strohman, 1989), HGF(Allen, Sheehan, Taylor, Kendall, 
& Rice, 1995; Tatsumi, Anderson, Nevoret, Halevy, & Allen, 1998), IGF(Musarò et al., 2001) 
and TNF-α(Y. P. Li, 2003). Nitric oxide has also been shown to indirectly induce satellite cell 
differentiation by stimulating MMP production.(Tatsumi, 2010) Upregulating MMPs causes 
further degradation of the ECM, releasing more growth factors confined within the 
ECM.(Tatsumi, 2010) Satellite cell division must take place not only to provide the cells 
necessary to replace damaged myofibers, but also to renew the stockpile of satellite cells needed 
for future regeneration. Renewal of skeletal muscle stem cells during a myogenic event will 
occur through the asymmetric division of satellite cells.(Dumont, Bentzinger, Sincennes, & 
Rudnicki, 2015) One daughter cell will be an activated cell that will differentiate to a myoblast 
and the other daughter cell will remain a satellite cell. The asymmetric division of satellite cells 
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is characterized by the presence of Myf5 in cells committed to myogenesis and the absence of 
Myf5 in cells that will remain stem cells.(Knoblich, 2008) These uncommitted satellite cells can 
undergo symmetric division to replenish the pool of satellite cells in preparation for the next 
regenerative event.(Shi & Garry, 2006) Alongside stem cell activation, myogenic cell migration 
is also initiated by cytokines to recruit regenerative cells to the injury site. Migration of satellite 
cells can occur before or after activation, but studies have shown that the rate of migration is 
higher before activation takes place.(Schultz, Jaryszak, & Valliere, 1985; Siegel, Atchison, 
Fisher, Davis, & Cornelison, 2009a) A transmembrane protein, CD34, appears to be important 
for satellite cell migration as CD34-deficient mice have reduced satellite cell motility.(Alfaro et 
al., 2011) Chemotactic cytokines are not the only type of molecule responsible for myogenic cell 
migration, MMPs also aid in the process by degrading the ECM surrounding the satellite 
cells.(Kaar et al., 2008) MMP1, MMP2, and MMP9 proteolyze the collagen fibers that make up 
the ECM(Kaar et al., 2008), but MMP action is attenuated by an upregulation in TIMP, an MMP 
inhibitor. Therefore increased expression of both MMPs and TIMPs is seen during skeletal 
muscle regeneration to facilitate regenerative cell chemotaxis without compromising the integrity 
of the ECM.(Karalaki, Fili, Philippou, & Koutsilieris, 2009; Nishimura et al., 2008)  
Myoblast proliferation begins after progenitor cells have been activated and migrate to 
the injury. A spike in pro-inflammatory cytokines, such as IL-6 and TNF-α, has been shown to 
take place concurrently to myoblast proliferation.(Allen et al., 1995) There are a number of 
pathways that can be activated or repressed to induce either proliferation of myoblasts or further 
differentiation. The JNK(Alter, Rozentzweig, & Bengal, 2008; Perdiguero, Ruiz-Bonilla, 
Serrano, & Muñoz-Cánoves, 2007) and NF-kB(Otis et al., 2014) pathways can both be activated 
to promote myoblast proliferation, while the JAK1/STAT1/STAT3 pathway suppresses genes 
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responsible for differentiation and pushes cells towards mitosis.(Sun et al., 2007) Suppressing 
premature complete differentiation allows for a more robust response to a skeletal muscle injury 
by increasing the pool of myogenic cells. The final steps of differentiation involve the repression 
of Pax7 and the increased expression of MyoD.(Olguin, Yang, Tapscott, & Olwin, 2007) Cells 
expressing MyoD will initiate the production of molecules associated with the contractility of 
mature myofibers.(Megeney, Kablar, Garrett, Anderson, & Rudnicki, 1996; Sabourin, Girgis-
Gabardo, Seale, Asakura, & Rudnicki, 1999) Myosin heavy and light chains, troponin, α-actinin, 
and muscle creatine kinase will all be produced after myogenin, a downstream product of MyoD, 
is expressed.(Davie et al., 2007) Myotubes in turn fuse to one another to form multinucleated 
myofibers. These nascent myofibers are identified by cross sectional views that show centrally 
located nuclei, contrasted with mature myofibers in which the nuclei are located at the periphery 
of the fiber.  
In addition to myofiber regeneration, ECM regeneration also must take place to restore 
the muscle to pre-injury condition. Fibroblasts within the tissue deposit new ECM when directed 
by cytokines released during the inflammatory stages. Muscle that receives a critical defect due 
to a massive wound or muscle compromised by disease will not regenerate and will instead 
develop a fibrotic scar. Myostatin is a pro-fibrotic growth factor responsible for inhibiting 
muscle regeneration and facilitating the proliferation of fibroblasts.(Z. B. Li, Kollias, & Wagner, 
2008) 
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C. Volumetric Muscle Loss 
  
If muscle sustains mild to moderate injury, such as contusions and small lacerations, 
satellite cells within the muscle are capable of replacing damaged myofibers and returning the 
muscle to full function.(Grogan, Hsu, & Skeletal Trauma Research Consortium, 2011; Mauro, 
1961; Turner & Badylak, 2012) However, in the case of volumetric muscle loss (VML), where 
more than 20% of muscle volume is lost due to severe trauma, satellite cells are incapable of 
replacing the damaged tissue and the muscle will suffer permanent functional deficit.(Grogan et 
al., 2011; Sicari et al., 2012; Wu, Corona, Chen, & Walters, 2012a) The loss of volume from the 
muscle not only removes contractile myofibers, it also removes a significant stockpile of satellite 
cells. The remaining muscle undergoes fibrosis at the injury site, limiting the future contractile 
potential.(Corona et al., 2013a; Meyer & Lieber, 2012) The effect VML has on a muscle is 
dependent on the joint angle and muscle length, as found by Garg et al. in 2015. They reported 
that strength deficits in VML-damaged muscles may be significantly worse in joint angles in 
which the muscle is in a shortened position, such as dorsiflexion of the tibialis anterior 
(TA).(Garg et al., 2015) They also noted that VML results in a persistent reduction of fiber 
length. Their study highlights the complexity of VML injuries and considerations that must be 
understood to regenerate skeletal muscle tissue. “Not only the gross loss of muscle tissue but also 
architectural and histologic adaptations of the remaining tissue underlie the persistent functional 
deficits. Therefore, approaching full strength recovery of VML injured muscle will require 
therapies that maximize the functional capacity of the remaining muscle tissue, promote de novo 
regeneration of muscle tissue, and integrate these tissues to re-establish the intrinsic properties of 
the original muscle.”(Garg et al., 2015) Clinically, there are few options available to physicians 
to treat VML and regenerate lost tissue.(Grogan et al., 2011) Autografts have been used although 
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they introduce an additional surgical site and cause donor site morbidity.(Fisher & Mauck, 2013; 
Grogan et al., 2011) 
 Initial studies of skeletal muscle autografts performed over 100 years ago showed that if 
muscle was implanted back into the body it would undergo fibrosis and/or necrosis. Muscle was 
replaced in frogs, rodents, and canines with researchers eventually concluding that muscle could 
not remain viable after being freely transferred into an autologous or homologous host. In 1906, 
Hildebrandt hypothesized that muscle could be transferred as long as the tissue remained 
innervated. He found that muscle rapidly deteriorated and underwent fibrosis except of portions 
that were in contact with the healthy tissue that surrounded the implant site.(Thompson, 1971) 
He discovered that nascent anastomosis between the healthy tissue and implanted tissue had kept 
the nearest myofibers alive.(Thompson, 1971) Other early animal studies have shown that even 
if an autograft retains its blood supply and vasculature, gradual atrophy and fibrosis of the 
muscle will take place if it is not innervated. Thus, muscles that do not have a blood supply and 
are not receiving stimuli from a motor neuron will undergo ischemia and lose contractility. 
However, in 1970 Thompson showed that free muscle autografts could be successfully 
transplanted in humans if the autograft was reinnervated by a motor neuron from the muscles 
surrounding the implant site. Thompson transplanted either the palmaris longus or extensor 
digitorum brevis to treat facial paralysis in 8 patients.(Thompson, 1971) By implanting the free 
autografts in contact with functioning facial muscles, the intact motor neurons from adjacent 
muscles were able to branch such that the terminal buds came into contact with the motor end 
plate. All of the patients were able to demonstrate voluntary control of implanted muscles after 4 
months and retained control through the end of the year and a half long study.(Thompson, 1971) 
Muscle flap autografts have been a treatment option for physicians treating VML for at least the 
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past 30 years.(Mase et al., 2010) Flap autografts differ from free autografts in that flap autografts 
remain attached to the origin of the muscle and preserve the connection to the systemic blood 
supply.(Klebuc & Menn, 2013) Many cases of flap autografts to repair the lower limb use the 
anterolateral flap to replace tissue lost in the anterior crural compartment of the lower limb.(T. 
Kim, Kim, Kim, & Lee, 2012; Lin, Lin, Yeh, & Chen, 2007) Functional recovery from this 
procedure is not expected as this intervention is used to create a favorable environment for soft 
tissue repair and for cosmetic reasons.(T. Kim et al., 2012) Free and flap muscle transfers are 
also used to improve functional outcomes of bone repair with or without bone allografts by 
providing a suitable environment for osteogenic repair.(N. Li, Yuan, Chen, Chen, & Jin, 2009; 
Masquelet, 2003) Similarly, in the upper extremity, physicians use free or flap muscle autografts 
to repair soft tissue damage.(Coulet, Boch, Boretto, Lazerges, & Chammas, 2011; Fan et al., 
2008; Fischer, Elliott, Kozin, & Levin, 2013; Lohse, Lee, & Watson, 2014; Vekris et al., 2008) 
There have been isolated cases of free muscle transfers being used to restore function, 
specifically in restoring elbow flexion to patients that have suffered brachial plexus 
injuries.(Coulet et al., 2011; Fan et al., 2008; Lohse et al., 2014; Vekris et al., 2008) 
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D. Skeletal Muscle Tissue Engineering 
  
Advances in tissue engineering have yielded researchers and physicians a number of 
treatment options for other tissues such as bone and skin.(Bi & Jin, 2013; Rossi, Pozzobon, & De 
Coppi, 2010) In contrast, very few options exist for skeletal muscle repair, although a number of 
scaffold-based and cell-based strategies are currently being developed.(Bursac, Juhas, & Rando, 
2015; Laumonier & Menetrey, 2016; Qazi, Mooney, Pumberger, Geissler, & Duda, 2015) 
Scaffolds that are designed for skeletal muscle tissue engineering are not unlike scaffolds used 
for other applications in the body.  They must promote the adhesion and proliferation of cells, 
they must be composed of biocompatible materials and they must provide the engineered tissue 
with properties similar to native tissue.  However, skeletal muscle tissue has several additional 
requirements of scaffolds designed to repair skeletal muscle.  Skeletal muscle tissue constructs 
must have parallel fibers to promote the formation of parallel myofibers, which are essential for 
contractile force, and must allow for vascularization and innervation in vivo.(Turner & Badylak, 
2012) Vascularization is exceedingly important because cells must have access to oxygen and 
needed biomolecules from the moment the cells are seeded onto the scaffold.(Levenberg et al., 
2005a) Innervation is necessary to provide electrical stimuli for the directed contractile force.  
3D scaffold integration with host vascular and nervous networks must take place for successful 
regeneration of skeletal muscle.(Bursac et al., 2015) Damaged or diseased skeletal muscle can 
also be repaired without the use a three dimensional scaffold.  Researchers have been able to 
repair a skeletal muscle defect using fibrin microthreads seeded with muscle-derived 
fibroblasts.(Page et al., 2011) The fibrin microthreads allowed the host to replace skeletal muscle 
tissue without forming considerable scar tissue as was seen in an untreated defect.(Page et al., 
2011) The fibrin microthread treated muscle was able to regain 80-95% of original tetanic force, 
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whereas untreated, defected muscle only had around 55% of the original tetanic force.(Page et 
al., 2011) 
Biologic and synthetic scaffolds have been developed to provide a stable environment for 
cell proliferation and the production of contractile tissue under in vitro and in vivo conditions.  
Biologic scaffolds include acellular extracellular matrix (ECM), collagen, hydrogels, and 
polymeric constructs which can be seeded with cells ranging from human stem cells to 
differentiated myoblasts.(Wolf, Dearth, Sonnenberg, Loboa, & Badylak, 2015) ECM scaffolds 
can have many different configurations; scaffolds can be therapeutically delivered as a powder, 
in sheets (either single-ply or laminate), as a hydrogel, or whole tissue 3D constructs.(Wolf et al., 
2015) ECM has been shown to be an effective scaffold in many translational applications and, in 
various forms, is currently an FDA-approved biomaterial.(Chen, Xu, Wang, & Zheng, 2009) 
ECM not only provides a scaffold for cell attachment, but host immune degradation of the ECM 
also provides a pro-regenerative environment in many applications.(S. F. Badylak, Dziki, Sicari, 
Ambrosio, & Boninger, 2016; J. L. Dziki, Sicari, Wolf, Cramer, & Badylak, 2016) 
 
ECM Scaffold Based Repair Strategies 
In recent years, many researchers have used ECM based scaffolds to repair skeletal 
muscle defects in animal models. The research group out of the University of Pittsburgh led by 
Dr. Stephen Badylak has been using ECM derived from the small intestine submucosa (SIS) or 
urinary bladder submucosa of pigs a therapeutic scaffold to repair various tissues and structures 
since 1995.  
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The first studies used the SIS as a vascular graft in canines.(S. F. Badylak, Lantz, Coffey, 
& Geddes, 1989; Lantz, Badylak, Coffey, Geddes, & Blevins, 1990) Through these initial 
studies, they addressed the biocompatibility of the graft and found that by stripping the cells, 
they reduced the rejection response of the host’s immune system, which is the principal 
challenge for any study involving the transplantation of whole organs or tissues. They also 
demonstrated decellularized porcine SIS is an effective scaffold, allowing for the infiltration of 
host cells while maintaining structural integrity of the entire tissue in conjunction with 
surrounding host tissue.(Lantz et al., 1990) The vascular grafts were gradually replaced by host 
cells and ECM which indicated to the researchers that complete recovery had taken 
place.(Sandusky Jr, Badylak, Morff, Johnson, & Lantz, 1992) This lead Badylak and his 
colleagues to use decellularized porcine SIS and the submucosa from the urinary bladder to 
repair a variety of tissues. They subsequently published papers on bladder wall, dural tissue, and 
esophageal repair using porcine SIS.(S. Badylak, Meurling, Chen, Spievack, & Simmons-Byrd, 
2000; Cobb, Badylak, Janas, Simmons-Byrd, & Boop, 1999; Kropp et al., 1995; Kropp et al., 
1996) They also used porcine SIS as a wound healing patch in a rodent model.(Prevel, Eppley, 
Summerlin, Sidner et al., 1995) 
Within the field of musculoskeletal repair, they investigated the regenerative capabilities 
of an SIS bioscaffold in tendon, bone, and muscle of animal models. The tendon repair study, led 
by Badylak, showed that a defect within the Achilles tendon in canines could be repaired using 
decellularized porcine SIS.(S. F. Badylak et al., 1995) By measuring the uniaxial longitudinal 
tensile strength, they determined that the repaired portion of the tendon had greater strength than 
the proximal or distal ends of the tendon 12 weeks post-recovery. The SIS bioscaffold had been 
degraded and replaced by host tissue 8 weeks after implantation according to 
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immunohistological analysis.(S. F. Badylak et al., 1995) The initial bone repair study, led by 
Suckow, showed that SIS rapidly repaired a long bone defect in Sprague-Dawley rats.(Suckow, 
Voytik-Harbin, Terril, & Badylak, 1999) The SIS performed similarly to demineralized cortical 
bone treatment by first allowing for cartilage formation which was interchanged with 
mineralized bone.(Suckow et al., 1999) The first study investigating the regenerative potential of 
SIS in a muscle defect model took place in 1995 using an abdominal wall defect model.(Prevel, 
Eppley, Summerlin, Jackson et al., 1995)  The abdominal wall defect model was developed using 
rats who received a 2cm x 2cm defect within the skeletal muscle of the abdominal wall. An SIS 
bioscaffold was placed into the defect. To assess skeletal muscle regeneration, Prevel and his 
group did qualitative histological analysis of thin muscle sections to determine that the SIS 
incorporated into the existing abdominal wall after two months with minimal inflammation and 
there was no evidence of host rejection of the donor tissue.(Prevel et al., 1995)  
More recently, research groups associated with Dr. Badylak and the University of 
Pittsburgh have published research on using porcine SIS to repair VML in animal models. In one 
study, Turner et al. made a defect in the distal third of the gastrocnemius muscle and proximal 
half of the associated Achilles tendon of canines.(Turner et al., 2010) While in another study, 
Sicari et al. made a defect in murine quadriceps.(Sicari et al., 2012) The techniques used in 
determining the effectiveness of the SIS in repairing the skeletal muscle defect in both studies 
were similar. The researchers looked at the vascularization of the wound site, the infiltration of 
myoblasts and nascent myofiber formation, and they observed the progressive degradation of the 
SIS scaffold in the wound site. They noticed that the repair proceeded similarly to the earlier 
abdominal wall defect models, with a rapid degradation on the bioscaffold, neovascularization, 
and myoblasts forming isolated myofibers within the defect.(Sicari et al., 2012; Turner et al., 
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2010) Badylak’s group relies on histological evidence of wound repair and muscle formation and 
does not use in vivo functional testing as a measure of regeneration, although they have reported 
on ex vivo functional testing.(Turner et al., 2010) In addition to investigating decellularized 
porcine SIS as a bioscaffold to repair VML, Wolf et al. compared the regenerative performance 
of SIS to ECM derived from decellularized skeletal muscle.(Wolf, Daly, Reing, & Badylak, 
2012) They observed differences in the biochemical composition of the ECM scaffolds, 
specifically: growth factors, glycosaminoglycans, and structural proteins of the basement 
membrane. However, using the same criteria as previous studies, they found that there was little 
difference between the regenerative capacities of the two bioscaffolds when used to repair an 
abdominal wall defect.(Wolf et al., 2012) They concluded that “superior tissue remodeling 
outcomes are not universally dependent upon homologous tissue derived ECM scaffold 
materials.”(Wolf et al., 2012) Another Sicari et al. study (again within the Badylak group) 
published a translational study using ECM derived from porcine urinary bladder to repair VML 
in a rat model and in five human patients.(Sicari et al., 2014) The ECM derived from porcine 
urinary bladder matrix (UBM) is structurally and biochemically very similar to ECM derived 
from porcine SIS. The UBM elicited functional improvement in three of the five human 
patients.(Sicari et al., 2014) Although the authors were careful not to call the response 
“regeneration” and instead referred to the recovery as constructive remodeling. The distinction 
between these terms was more clearly explained in a recent review by Badylak et al. in 2016. 
The response of the host to the ECM bioscaffold is similar to innate repair mechanisms with 
infiltration of macrophages and a transient pro-inflammatory environment, followed by 
myogenesis and ECM remodeling, but the processes are not identical since current ECM-based 
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repair modalities are accompanied by long-lasting, though isolated, fibrosis at the injury site and 
no study has yet shown complete functional recovery from VML.(S. F. Badylak et al., 2016)  
Badylak’s group has since performed a larger clinical study with a 13 patient cohort. The 
patients had a variety of defect sites and mechanisms of injury but most experienced functional 
recovery after treatment with porcine ECM bioscaffolds (SIS, UBM, and dermal ECM). The 
authors reported a 37% improvement in functional strength and a 27% increase for range of 
motion tasks.(J. Dziki et al., 2016) This study provides evidence to justify the further exploration 
of ECM bioscaffolds as a therapy for VML, but the percent improvement from this study do not 
necessarily correspond to expected clinical outcomes due to the diversity of VML injury 
locations and severity. These patients also were outside the acute injury response phase and had 
undergone several previous surgeries for debridement and/or tenolysis.(J. Dziki et al., 2016) 
Animal models used for investigating VML repair typically deliver scaffolds and/or cells 
immediately after creation of a VML injury. Therefore it is difficult to compare functional 
recovery results from this human study to results seen in small or large animal models. This 
study also self-identifies several limitations with respect to the lack of a control treatment (scar 
debridement and prescribed physical therapy), the presence of varying comorbidities even with 
similar implantation sites, and failing to control for the placebo effect.(J. Dziki et al., 2016) 
However, this study, published online in July 2016, is currently the largest clinical study to date 
to explore ECM bioscaffold therapies for VML in human patients.  
In addition to investigations with decellularized porcine submucosa scaffolds, Dr. 
Badylak and his group has advanced the characterization and use of decellularized scaffolds 
more broadly.(Gilbert, Sellaro, & Badylak, 2006) Decellularization is a process which removes 
the cellular components from a tissue leaving behind the intact ECM.(Gilbert et al., 2006) 
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Decellularized tissue is promising as a biologic scaffold because it retains the biochemical and 
morphological structure of the native ECM while having dramatically lower antigenicity than an 
allograft because it lacks foreign cell antigens.(Gilbert et al., 2006) Decellularization of tissues 
and whole organs can be accomplished through the use of chemical agents such as: surfactants, 
detergents or osmotic solutions.(Gilbert et al., 2006; Gillies, Smith, Lieber, & Varghese, 2010) 
Decellularization has been used to produce whole organ scaffolds for the heart(Ott et al., 2008), 
liver(Uygun et al., 2010), lungs(Ott et al., 2010), and kidneys(Sullivan et al., 2012).  Whole 
organ decellularization in many cases has been achieved through the use of vascular 
perfusion.(Ott et al., 2008; Ott et al., 2010; Sullivan et al., 2012; Uygun et al., 2010) The major 
inlets and outlets (arteries and veins) and the capillary network of organs allow for perfusion of 
the entire organ.  
One of the hallmark papers of decellularized tissue was published by Ott et al. in Nature 
Medicine in 2008. They sought to decellularize a mammalian heart and subsequently return cells 
to the resulting scaffold in an attempt to engineer a functional “bioartificial” heart.(Ott et al., 
2008) They successfully decellularized the heart and repopulated the scaffold with neonatal 
cardiomyocytes, fibrocytes, endothelial cells, and smooth muscle cells. Although the bioartifical 
heart was responsive to electrical and chemical stimuli after 8 days, the contractile force only 
produced 2% of adult rat heart function. They did, however, report rhythmic depolarizations and 
contractions up to 5 minutes after the heart was removed from electrical pacing. The authors also 
stated that recellularization of the scaffold was incomplete as only 34% of tissue cross-sections 
were populated by injected cells.(Ott et al., 2008) While this study left a lot to be improved upon, 
it demonstrated the potential that decellularization had as a method for fabricating scaffolds with 
regenerative capacity.  
16 
 
 While most skeletal muscle lacks the major arteries and veins used for perfusion 
decellularization, skeletal muscle can also be decellularized to form an ECM-based scaffold. 
Scaffolds composed of decellularized muscle are unique because they retain the parallel 
alignment of the native muscle from which they were obtained and pores for cell attachment left 
by the previous cells.(Wilson, Terlouw, Roberts, & Wolchok, 2016)  Decellularization of 
skeletal muscle can be accomplished through the use of chemical agents such as: surfactants, 
detergents or osmotic solutions.(Gilbert et al., 2006)  Decellularized skeletal muscle (DSM) 
lacks the antigenicity of an allogenic transplant but requires the infiltration of host cells and 
revascularization with associated integration into the host vasculature to produce functioning 
myofibers.  
Several research groups around the world are currently exploring the use of DSM as a 
scaffold to repair VML in animal models. In 2010, Merritt et al. published a study in Tissue 
Engineering in which they used DSM along with bone marrow-derived mesenchymal stem cells 
to repair a VML injury in the gastrocnemius of a rat.(Merritt et al., 2010) The peak isometric 
contractile force produced by the muscle repaired with ECM+cells was 84% of the uninjured 
contralateral muscle after a 42 day recovery period. The authors also noted a dense population of 
desmin+ cells in the defect area of ECM+cells repaired muscles as well as significantly more 
vWF+ blood vessel ingrowth.(Merritt et al., 2010) Results confirming this robust regenerative 
capacity of DSM in VML injuries have been reported in other research groups.  
In a 2011 Biomaterials article, Perniconi et al. presented research in which most of a 
murine TA was removed, leaving only the distal tendon and enough muscle at the tibial origin to 
anchor a DSM scaffold.(Perniconi et al., 2011a) The authors did not perform any functional 
testing but described a pro-myogenic environment with capacity to support the de novo 
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formation of myofibers after implantation into a VML injury. The authors tracked the 
degradation of the accelular scaffold over four weeks and noted that it remained stable during 
initial macrophage invasion and was gradually degraded as host myoblasts migrated to the defect 
site. Centrally located nuclei were observed in the newly formed myofibers, indicative of skeletal 
muscle regeneration.(Perniconi et al., 2011a) 
Repair of VML is not the only application which is being researched to investigate the 
regenerative potential of DSM. DeQuach et al. developed an injectable skeletal muscle matrix 
hydrogel to repair peripheral artery disease (PAD) in a rat hindlimb ischemia model.(DeQuach et 
al., 2012) In order to create ischemia, the femoral artery was resected in a rat model. One week 
post-hindlimb ischemia, either DSM hydrogel or collagen hydrogel was injected intramuscularly 
below the site of the initial defect. Arteriole density was significantly greater in the DSM 
hydrogel compared to collagen at 3, 5, and 7 days post-injection. The authors also reported a 
significant increase in the number of desmin+ cells that co-expressed Ki67, an indicator for 
proliferating satellite cell, present at the site of DSM hydrogel injection.(DeQuach et al., 2012) 
 
Cell Based Repair Strategies 
Many researchers in the field of skeletal muscle regenerative medicine tout the 
advantages of “off the shelf” therapies such as DSM derived ECM compared to cell-based 
therapies.(Swinehart & Badylak, 2016) The disadvantages of cell-based therapies include: 
inadequate supply of fresh donor cells, difficulty delivering cells, and potential for implanted 
cells to undergo transdifferentiation, leading to cancerous growth.(Dumont et al., 2015) The 
inadequate supply of donor cells is due to several reasons. One of which is due to the host 
rejection response typically associated with whole organ donation. Stem cells are usually 
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autologous and harvested from many different sources within the patient’s body to include many 
different cell types. However, the first stem cell transplants were performed using allogeneic 
myoblasts to treat Duchenne Muscular Dystrophy (DMD). Although researchers had success 
initially with preclinical animal trials, the results from the first clinical trials were 
unsuccessful.(Huard et al., 1992; Huard et al., 1994; Kinoshita et al., 1994; Skuk, 2012) The 
conclusions drawn from these studies were that allogeneic myoblasts were not an effective 
treatment for DMD. Only 25% of the donor myoblasts remained viable after three days in two 
studies which was explained in a subsequent study that insufficient immunosuppressive therapy 
led to the host destroying most of the implanted myoblasts.(Guérette, Asselin, Skuk, Entman, & 
Tremblay, 1997) Almost 10 years later, Skuk et al. found that the implanted myoblasts did not 
migrate more than 200μm from the injection site.(Skuk et al., 2006) Another study hypothesized 
that the myoblasts had undergone precocious differentiation leading to a much smaller pool of 
myoblasts and by delaying cell cycle exit into asymmetric differentiation, the implanted pool of 
myoblasts was able to migrate further into the tissue.(Riederer et al., 2012) Other muscle derived 
cells have been indentified and studied for their impact on muscle regeneration, such as: CD133+ 
progenitor cells, muscle derived stem cells, multipotent perivascular progenitor cells.(Meng et 
al., 2014; Sampaolesi et al., 2006; Zheng et al., 2007) Studies using these cell types have been 
limited in scope and have not been used in clinical trials other than to determine the safety of 
delivery methods.(Cossu et al., 2015)  
Mesenchymal stem cells (MSCs) are another broad stem cell type that have been used as 
a cell source for skeletal muscle tissue engineering. MSCs are precursor cells which eventually 
form the tissues of the mesoderm through chondrogenic, osteogenic, adipogenic, or myogenic 
differentiation.(Sicari, Dearth, & Badylak, 2014) The sources of donor MSCs used to investigate 
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muscle repair range from bone marrow and adipose tissue to placenta and umbilical cord.(Erices, 
Conget, & Minguell, 2000; Jiang et al., 2002; Scherjon et al., 2004; Zuk et al., 2001) Bone 
marrow derived MSCs (BM-MSCs) have been shown to provide a dose dependent effect on 
functional recovery from a crush injury.(Winkler et al., 2008) They have also been shown to 
interact with the microenvironment at the defect site to induce paracrine signaling with the host’s 
own pro-inflammatory or myogenic cells.(Cizkova et al., 2011; Gang et al., 2009) Adipose 
derived stem cells (ADSCs) are an additional type of MSC that have been used in small animal 
hindlimb repair models. In 2010, Kang et al. found that injections of ADSCs into the ischemic 
hindlimb of a mouse improved perfusion after three days and had contributed to new myofiber 
formation after four weeks post-injury.(Kang et al., 2010) Work more recently by Kesireddy, has 
shown that while ADSCs do not increase myogenesis to the extent of muscle derived progenitor 
cells, they induce greater angiogenesis at the wound site and thus provide similar therapeutic 
outcomes within the context VML repair.(Kesireddy, 2016) Finally, umbilical cord blood (UCB) 
derived MSCs have been shown to have high myogenic potential by Pesce et al. when used in an 
ischemic hindlimb models.(Pesce et al., 2003) Like other MSCs, UBC derived MSCs have the 
potential to not only induce myogenesis but promote angiogenesis and deliver paracrine signals 
that encourage differentiation of host satellite cells and other progenitor cells.(Sicari et al., 2014) 
 
Skeletal Muscle Repair with Minced Muscle 
One novel approach for reducing the complexity of satellite cell delivery is the use of 
minced muscle (MM). MM is derived by mincing a small volume of muscle into pieces smaller 
than 1-2mm.(Corona et al., 2013b) MM differs from other cell-based therapies by delivering 
more than just progenitor cells to the injury site; basement membrane fragments, damaged 
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myofibers, and ECM captive growth factors are also present at implantation.(Corona et al., 
2013b) If taken from around the area of the defect site, MM would not require an additional 
surgical site. In 2013, Corona et al. from the United States Army Institute of Surgical Research at 
Fort Sam Houston, published a paper on the use of autologous minced muscle grafts. This 
research further explored the regenerative capacity of minced muscle which had first been 
observed by Studinsky and Carlson in 1964 and 1972, respectively.(Carlson, 1968; Studitsky, 
1965) Corona et al. first determined the proliferative capacity of the MM by culturing it on 
collagen coated dishes. They observed increasing nucleic acid out to 14 days and increasing 
numbers of desmin-positive cells, indicating that not only were cells proliferating but that 
myogenesis was occurring. Using immunohistochemical staining the authors also found that the 
expression of Pax7, CD31, myogenin, embryonic myosin heavy chain (emb-MHC), and CD163 
were all significantly higher in MM treated VML injuries than non-repaired VML 
injuries.(Corona et al., 2013b) They then used a rat TA model for VML injuries and implanted 
the defected muscle orthotopically back into the defect site after mincing in into 1mm3 
fragments. The contralateral limb was untreated to serve as a control and the rats were given an 
eight or sixteen week recovery period.  The mass of the repaired TA was 11 and 21% heavier 
than unrepaired TAs after eight and sixteen weeks, respectively. The MM-treated limbs also 
produced ~14% more isometric torque at 16 weeks post-injury than unrepaired limbs. Motor 
endplates were also observed in regenerated muscle fibers using α-bungarotoxin staining at 8 
weeks post-injury. They also determined that the fibers were innervated by repeatedly 
stimulating the muscle to deplete glycogen storage in innervated fibers. Glycogen levels of in the 
remaining muscle mass on the defected limb were similar to glycogen levels in the defect repair 
and both were significantly lower than non-stimulated muscle. Thus indicating that the nascent 
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myofibers within the defect area underwent glycogen depletion and were therefore 
innervated.(Corona et al., 2013b) The authors also identified several challenges and limitations 
to autologous transfer of MM to treat VML, the primary challenge being the introduction of a 
second surgical site on the patient to harvest skeletal muscle tissue. Nevertheless, since few other 
strategies to repair VML exist, Corona et al. concluded that “the use of minced muscle autografts 
is an appropriate standard for the future advancement of VML therapies.”(Corona et al., 2013b)  
The United States Army Institute of Surgical Research at Fort Sam Houston has 
conducted further studies exploring the regenerative potential of MM by expanding the minced 
autograft in a collagen hydrogel. The rationale for this 2015 study, authored by Ward et al., was 
that donor muscle tissue was limited and expansion and co-delivery with a collagen hydrogel 
could limit the amount of donor tissue necessary to facilitate regeneration of a VML 
injury.(Ward, Ji, & Corona, 2015) The goal of this study was to determine the minimum volume 
of MM needed to obtain functional outcomes consistent with a 100% volume MM 
autograft.(Ward et al., 2015) The treatment groups the authors tested were 0%, 25%, 50%, and 
100% MM with a volume of collagen to equal 400μL, the estimated size of the defect created in 
the TA muscle of male Lewis rats. The authors reported that the 50% autograft provided 
functional outcomes similar to 100% autografts with respect to peak tetanic force. However, the 
number of de novo fibers regenerating in the defect site of the 50% autograft were half the 
number of myofibers developing in the defect site of the 100% autograft. Another key finding 
was that the average fiber area was smaller in 50% and 100% autografts than fibers found in 
uninjured, control muscle tissue.(Ward et al., 2015)  
In addition to exploring the use of MM autografts to repair VML in animal models, the 
United States Army Institute of Surgical Research at Fort Sam Houston, led by Dr. Corona has 
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contributed to the field of skeletal muscle tissue engineering by providing evidence against the 
use of acellular ECM implant alone to repair VML injuries. They have published several papers 
providing evidence counter to many of the articles published by the Badylak research group, 
who, as previously discussed, has promoted the use of porcine-derived SIS or UBM scaffolds to 
repair skeletal muscle tissue.(Aurora, Roe, Corona, & Walters, 2015; Corona et al., 2013a) In 
one study, authored by Aurora et al., the U.S. Army research group tested the regenerative 
capacity of porcine UBM and rat-derived decellularized muscle ECM (m-ECM) and compared 
functional outcomes and histological data to unrepaired muscle and muscle repaired using an 
autograft.(Aurora et al., 2015) The autograft repair in this instance was simply the muscle 
removed by creating the VML defect and suturing it orthotopically back into the defect site. The 
UBM graft improved the functional strength of the muscle by 17% after 16 weeks of recovery 
when compared to unrepaired muscle. However, the autograft repair group had significantly 
higher functional recovery than the acellular repair and after 16 weeks had produced 83% of the 
force generated by an uninjured contralateral limb. Histological analysis of the defect site for the 
treatment groups provided evidence that very little de novo fiber development was taking place 
in muscles repaired with acellular grafts.(Aurora et al., 2015) The authors reported that the 
number of myosin+ fibers was 100 times higher in the defect area of autograft repaired muscles 
compared to the defect area of muscles repaired with either UBM or m-ECM acellular grafts. 
They also noted that fiber formation in acellular graft repaired muscle at eight weeks post-
implantation was only taking place within 200-300μm of the defect margins and that by 16 
weeks, there were no early developing muscle fibers. The collagen deposition measured in the 
defect area of UBM repaired muscles remained consistent with values seen in unrepaired muscle, 
whose self-repair mechanism is permanent fibrosis. These observations led researchers to 
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conclude that acellular scaffolds, while providing modest functional recovery, do not facilitate 
myogenesis.(Aurora et al., 2015) Moreover, any improvements in muscular force output are 
likely due to the creation of functional fibrotic tissue that lacks the contractility of normal 
skeletal muscle tissue but stabilizes and links remaining contractile myofibers.(Aurora et al., 
2015)  
Another aspect within studies conducted by Dr. Corona’s group which adds value to the 
field of skeletal muscle tissue engineering is that they investigate the effect rehabilitation has on 
functional recovery in animal VML models. They have reported that exercise, such as running 
wheels for rodents, does not seem to improve functional recovery for defected muscles repaired 
with acellular scaffolds.(Aurora et al., 2015) Animals receiving the same therapeutic intervention 
but with one half of the group having access to a voluntary running wheel and the other half 
having no access to an exercise wheel, had no significant differences in force production or 
tissue composition.(Aurora et al., 2015) In a previous study, Aurora et al. found that physical 
rehabilitation improved force production (17% improvement in peak isometric torque) and led to 
a 13% increase in muscle weight of animals that had an unrepaired VML injury.(Aurora, Garg, 
Corona, & Walters, 2014) But, wheel running did not alter the morphological characteristics of 
the unrepaired muscle; there was no additional myogenesis nor fiber hypertrophy in the muscles 
receiving a VML injury, regardless of rehabilitation.(Aurora et al., 2014) There was, however, an 
up-regulation of pro-fibrotic genes (Collagen I and TGF-β) in the unrepaired muscles of rats who 
had access to the running wheel.(Aurora et al., 2014)  
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Synthetic Scaffold Based Repair Strategies 
Synthetic materials manufactured into scaffolds for skeletal muscle tissue engineering 
have been and are currently being investigated for their regenerative capacity as a therapy for 
VML.  Synthetic scaffolds have several key advantages over biologic scaffolds from an 
engineering standpoint. They can be manufactured with precise specifications with respect to 
composition and architecture, and materials used in synthetic scaffolds have been better 
characterized that many biologic scaffolds.(Wolf et al., 2015) While these are advantages for the 
consistent, customizable, and high-throughput manufacture of tissue engineering scaffolds and 
allow for more precise characterization, synthetic scaffolds have not had more success than 
biologic scaffolds when used in animal models for skeletal muscle tissue engineering. Several 
types of polymers have been considered and evaluated for their potential as repair modalities for 
skeletal muscle trauma, they include: poly(glycolic acid) (PGA), poly(lactic acid) (PLA), 
poly(lactic-co-glycolic acid) (PLGA), poly(caprolactone) (PCL), polypropylene, and 
polyurethanes.(Wolf et al., 2015)  
Polypropylene was one of the first biomaterials used for tissue engineering due to its 
relative bio-inertness. However, in recent years, it has not been used prevalently as bio-
absorbable materials have been shown to be more appropriate due to the tendency of a host’s 
immune system to encapsulate any material that does not degrade readily.(Anderson, Rodriguez, 
& Chang, 2008) Permanent encapsulation with fibrotic tissue would preclude the primary 
function of any material used to facilitate the regeneration of contractile muscle tissue. 
PGA scaffolds have been in use for the past 17 years to repair skeletal muscle tissue. The 
initial PGA study, authored by Saxena et al., found that by seeding a primary cell line of 
myoblasts onto PGA absorbable mesh and implanting the construct into a Fisher 344 rat, they 
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could regenerate tissue that resembled skeletal muscle.(Saxena, Marler, Benvenuto, Willital, & 
Vacanti, 1999) Immunohistochemistry revealed that 45 days post-implantation, cells within the 
stands of the degrading synthetic graft stained positive for α-sarcomeric actin and desmin. The 
graft was also vascularized, however, the implantation site used in this study was the 
omentum.(Saxena et al., 1999) Although this paper provides evidence of the biocompatibility of 
the construct, it cannot be extrapolated to include myoblast-seeded PGA as an appropriate 
scaffold for VML unless functional testing and/or orthotopic implantation within a defected 
skeletal muscle is performed.  
PLA has only been used as a substrate upon which C2C12 (mouse skeletal muscle cell 
line) and HSKM5 (human skeletal muscle cell line) were attached and their viability and 
proliferative response was observed and reported in a paper authored by Cronin et al..(Cronin et 
al., 2004) The PLA, as a fiber and as a film, was coated with either ECM gel, gelatin, 
fibronectin, or laminin before cells were seeded. ECM-coated PLA outperformed other scaffolds 
with respect to cell attachment and expression of skeletal muscle related genes.(Cronin et al., 
2004) However, the in vitro nature of this study limits the impact PLA could potentially have as 
a therapeutic scaffold for skeletal muscle tissue engineering. 
PLGA scaffolds are an attractive material for scaffold fabrication due to the nontoxicity 
of its degradation products: lactic acid and glycolic acid. Many studies have been performed 
under in vitro conditions to fabricate biomimetic constructs for a variety of applications, 
including skeletal muscle repair. A paper, authored by Shandalov et al., reported promising 
results with a stem cell seeded PLA-PLGA scaffold implanted into an abdominal wall defect 
model in a mouse.(Shandalov et al., 2014) Before orthotopic implantation into the abdominal 
wall, the researchers implanted the scaffold around the femoral artery and vein and isolated the 
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construct from surrounding tissue. This in vivo preconditioning initiated vessel formation within 
the scaffold and the new vasculature survived through the subsequent removal and re-
implantation into the abdominal wall.(Shandalov et al., 2014) They observed anastomosis with 
the host vasculature and robust perfusion of the scaffold 2 weeks postimplantation. There have 
other in vivo studies in animal models using PLGA scaffolds, although results from these studies 
have no provided evidence of functional recovery from extremity VML repair.(Laschke et al., 
2008; Levenberg et al., 2005b) 
PCL is another promising synthetic biomaterial that has been investigated for its 
compatibility as a scaffold for skeletal muscle tissue engineering. Some of the best examples of 
PCL scaffolds are ones that have been fabricated using electrospinning, a method that is used to 
arrange synthetic constructs by extruding a polymer onto a charged plate. By varying the charge 
and deposition rate, researchers are able to create a scaffold with aligned microstructure, suitable 
for muscle progenitor cell adhesion and proliferation.(Choi, Lee, Christ, Atala, & Yoo, 2008a)  
Electrospun PCL scaffolds have been fabricated with aligned fibers, which has been shown to be 
important for myotube formation in vitro.(Choi et al., 2008a) 
Polyurethane scaffolds have also been developed using electrospinning fabrication 
techniques. Researchers have reported that multiple skeletal muscle cell lines, such as: C2C12, 
L6, and human satellite cells, have proliferated and differentiated on polyurethane scaffolds.(S. 
A. Riboldi, Sampaolesi, Neuenschwander, Cossu, & Mantero, 2005) Polyesterurethane scaffolds 
have been developed and explored due to their favorable mechanical properties. PLA, PGA, and 
PLGA fibers have a high tensile modulus and researchers have suggested that this would prevent 
them from being used in the dynamic niche of skeletal muscle tissue engineering.(S. A. Riboldi 
et al., 2005) Polyesterurethane fibers are elastomeric and have been shown to provide a suitable 
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substrate for skeletal muscle progenitor cell attachment, proliferation, and differentiation.(S. 
Riboldi et al., 2008; S. A. Riboldi et al., 2005; Sirivisoot & Harrison, 2011) 
One benefit to using synthetic scaffolds is that their morphology can be tuned for a 
specific application. Synthetic biomaterials used for skeletal muscle tissue engineering have been 
fibers, mesh, hydrogels, and foams. Synthetic scaffolds are designed to mimic the ECM with 
respect to the alignment of fibers and pore size.(Klumpp, Horch, Kneser, & Beier, 2010) 
Although synthetic scaffolds may not have the exact biochemical composition of native ECM, 
researchers are able to direct the organization of the fibers.(Aviss, Gough, & Downes, 2010; 
Choi et al., 2008a) Hydrogels lack any organization for cell attachment and researchers must 
modify the surface with microfabrication techniques if a hydrogel is to be used in skeletal muscle 
tissue engineering.  Micropatterning with soft photolithography, a technique used in 
microfluidics, can create channels on which cells can adhere and proliferate.(Huang, Lee, & Li, 
2010a)   
 Many synthetic scaffolds proposed as alternatives to repair skeletal muscle tissue trauma 
have only been characterized under in vitro conditions and only with a cursory knowledge of 
skeletal muscle tissue morphology and physiology. Although cell viability and proliferation is 
important to establish for any skeletal muscle scaffold suggested for implantation into even a 
small animal model, more rigorous in vivo testing must be undertaken before synthetic and tissue 
engineered skeletal muscle have any translational applications. Skeletal muscle regeneration 
after a VML injury is a complicated process with many spatio-temporal considerations to 
address. Synthetic scaffold research to this point has been focused on developing in vitro 
biomimetic skeletal muscle, but little advancement has taken place in terms of in vivo testing 
within skeletal muscle tissue beyond biocompatibility and host cell infiltration analysis, 
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excluding work done in abdominal wall defect models. However, there are some tissue 
engineered constructs that have been studied for contractile force production in vivo and even 
within a VML injury. 
  
Engineered Skeletal Muscle Tissue 
In addition to developing scaffolds, some researchers have sought to engineer skeletal 
muscle tissue from cells. Tissue engineered skeletal muscle can function as a model for 
pharmacological research, a tool for understanding embryological development and/or 
myogenesis, or a therapeutic intervention for repairing skeletal muscle trauma. Two separate 
groups have been using tissue engineered skeletal muscle under in vivo conditions and, more 
importantly, within skeletal muscle tissue. Dr. Juhas and Dr. Bursac from Duke University and 
Dr. Larkin from the University of Michigan have developed constructs that produce contractile 
force and, in the case of Dr. Larkin’s research, have successfully integrated into damaged host 
muscle. Juhas et al. fabricated engineered skeletal muscle by first molding a MatriGel hydrogel 
with primary rat myoblasts in a PDMS mold. The authors noted the first objective was to create 
an in vitro environment that more accurately reproduces the in vivo environment of the 
myogenic tissue niche. Satellite cell proliferated and differentiated under in vitro conditions and 
the researchers directed the development of cells into an engineering skeletal muscle tissue. The 
engineered construct was capable of contractile force generation before it was implanted into a 
dorsal window on a rat. At 2 week postimplantation, the construct was producing 3.5x more 
contractile force than the pre-implanted engineered muscle. The engineered muscle also showed 
robust vascular ingrowth from the host vasculature and a 40.7% increase in myofiber diameter. 
The authors reported that engineered muscle appeared to have a myogenic response to 
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implantation even though it was not within a skeletal muscle niche. In addition, the authors 
reported vigorous recovery from an in vitro cardiotoxin injury. Juhas et al. concluded that the 
results from their research supports using in vitro engineered muscle as a tool for drug and 
toxicology studies. 
 Dr. Larkin’s group has also developed tissue engineered muscle tissue and have used 
their construct to specifically repair VML in an animal model. In a paper authored by VanDusen 
et al., they report that a rat TA muscle with a VML injury receiving therapeutic intervention with 
their construct produced significantly more in vivo tetanic contractile force than an unrepaired 
TA.(VanDusen, Syverud, Williams, Lee, & Larkin, 2014a) The fabrication of their engineered 
muscle used techniques similar to those by Dr. Bursac’s group. Muscle progenitor cells, along 
with isolated bone marrow cells, were harvested from the soleus muscle of 120 – 150 g female 
Fisher 344 rats. Bone marrow cells were cultured in appropriate media to produce engineered 
bone-tendon anchors used to implant the engineered muscle tissue. The muscle progenitor cells 
were grown to confluence until elongating myotubes began to form and the monolayer was 
delaminated and rolled into a cylindrical muscle construct. In addition to determining in vivo 
peak tetanic force, the researchers also evaluated the regenerative potential of the engineered 
muscle through histological data. Fluorescent imaging revealed aligned myofibers that had 
developed advanced sarcomeric structure. At 28 days post-implantation, there was evidence of 
innervation of the engineered construct through IHC staining for pan-axonal filaments and the 
presence of ACh receptors through α-bungarotoxin staining. Immunostaining with CD-31 also 
showed the presence of a well-developed capillary network throughout the engineered muscle 
tissue. The capillary network was morphologically similar to those found in native muscle, with 
vessels running parallel to the muscle fibers. The results from this study and others performed by 
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Dr. Larkin’s group have motivated further investigations using engineered muscle tissue to repair 
VML in larger volume models and to explore entire muscle replacement. 
 As previously discussed, skeletal muscle tissue is highly aligned and the force production 
of a muscle is heavily influenced by the muscles architecture. Muscle architecture, the 
arrangement of muscle fibers in relation to the axis of force generation, is constrained by the 
length of the muscle, the length of myofibers, the pennation angle, and the physiological cross 
sectional area (PCSA).(Lieber & Friden, 2000) Even in pennate muscles, adjacent myofibers 
have parallel alignment and the surrounding ECM is highly uniform in direction. When 
designing bioreactors for tissue engineered skeletal muscle, researchers are deliberate in 
developing alignment within their constructs.(Aubin et al., 2010; Aviss et al., 2010; Huang, Lee, 
& Li, 2010b; Vandenburgh & Karlisch, 1989) Parallel alignment of myofibers has been shown to 
be important for developing phenotypically normal muscle tissue under in vitro 
conditions.(Aubin et al., 2010; Lam, Huang, Birla, & Takayama, 2009; Vandenburgh & 
Karlisch, 1989; Wang, Wu, Guo, & Ma, 2015) Researchers obtain parallel alignment through 
micropatterning(Cimetta et al., 2009; Flaibani et al., 2009; Huang et al., 2010a; Shimizu, Fujita, 
& Nagamori, 2009), aligned deposition of fibers(Aviss et al., 2010; Choi, Lee, Christ, Atala, & 
Yoo, 2008b; Wang et al., 2015), or by selecting a scaffold that has native parallel alignment. 
Myofiber alignment indicative of a mature muscle phenotype has also been induced in vitro 
using bioreactors that deliver mechanical or electrical stimulation to cells and/or tissue 
constructs.(Ahadian et al., 2013; Boonen et al., 2010a; Donnelly et al., 2010; Flaibani et al., 
2009; Grossi, Yadav, & Lawson, 2007; Langelaan et al., 2011; Powell, Smiley, Mills, & 
Vandenburgh, 2002; Vandenburgh & Karlisch, 1989)  
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Table 2: Highlighted VML repair studies. 
VML Repair  
Strategy 
Animal 
Model 
Outcome Authors 
DSM + MSCs Rat (Gastroc.) Improved contractile force. 
Evidence of myogenesis 
with addition of MSCs. 
Merritt et al., 2010 
SIS Canine (Gastroc.) No improvement in 
contractile force. 
Neovascularization and 
formation of isolated 
myofibers within defect. 
Turner et al., 2010 
DSM Murine (TA) 
(Whole muscle) 
Gradual degradation of ECM 
scaffold. Myoblast migration 
to defect. Centrally located 
nuclei in myofibers. 
Perniconi et al., 2011 
SIS Murine 
(Quadriceps) 
Rapid degradation of ECM 
scaffold. Vascularization and 
nascent myofiber formation 
at the defect site. 
Sicari et al., 2012 
DSM 
 
 
SIS 
Rat 
(Abdominal wall) 
No remarkable difference 
between SIS and DSM. 
Isolated de novo myofiber 
formation and fibrosis at 
defect site. 
Wolf et al., 2012 
MM Rat (TA) Greater contractile force. 
Motor endplates in new 
myofibers.  
Corona et al., 2013 
Engineered 
Skeletal  
Muscle 
Rat (TA) Signficant improvement in 
contractile force when 
compared to unrepaired 
VML muscle. Blood vessel 
ingrowth and innervation. 
VanDusen et al., 2014 
MM + collagen 
hydrogel 
Rat (TA) 50% MM produced 
contractile force similar to 
100% MM, but had fewer 
new myofibers. Average 
fiber area smaller than 
control muscle. 
Ward et al., 2015 
Autograft 
 
 
UBM 
 
 
DSM 
Rat (TA) Autograft had greatest force 
recovery (83%) compared to 
acellular scaffolds. Myofiber 
formation only 200-300μm 
from defect margins. UBM 
treated muscle had fibrosis 
similar to unrepaired muscle. 
Aurora et al., 2015 
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E. Objective 
 
The foundational goal of this research is to provide additional evidence to the following 
hypothesis: ECM provides a therapeutic platform to aid in the regeneration of skeletal muscle 
after volumetric muscle loss. 
What is proposed is to improve methods of obtaining DSM, use DSM to repair VML in 
an animal model, and to explore the effect of alignment and misalignment of VML repair 
strategies within a defected muscle. We will use minced muscle as a source of cells and 
additional signaling molecules to improve muscle regeneration. The use of minced muscle alone 
has been shown to improve muscle regeneration and we intend to further explore its potential 
when co-delivered with DSM. We will then explore the microenvironment between an autograft 
and a muscle with a VML injury. In doing so, we hope to study the effect alignment has on 
fibrosis and/or myogenesis at the interface of the graft and damaged muscle. 
We seek to further explore VML repair by investigating the effect scaffold alignment has 
at the interface of the damaged muscle and tissue repair construct. While many researchers have 
established the importance of alignment when engineering or selecting an effective scaffold, no 
studies have investigated the effect of alignment or misalignment between the myofibers of the 
autograft and the myofibers of muscle that has sustained a VML injury. By first investigating the 
effect of autograft alignment within a VML defect on the functional recovery, we hope to guide 
our future repair strategies including DSM and cell-derived ECM scaffolds. 
A brief outline of the approach is as follows: 
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• A perfusion decellularization system will be developed to produce skeletal muscle ECM 
scaffolds.  
• Scaffolds (diffusion and perfusion decellularized) will be characterized to ensure the 
perfusion process does not negatively alter ECM.  
• DSM with and without the addition of MM will be implanted within a defected muscle to 
repair VML in an animal model.  
• The final portion of this study will be to explore the effect of alignment has on the 
regenerative potential of an autograft to repair VML.  
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Abstract 
The implantation of decellularized tissue has shown effectiveness as a strategy for the treatment 
of volumetric muscle loss (VML) injuries. The preparation of decellularized tissue typically 
relies on the diffusion driven removal of cellular debris. For bulky tissues like muscle, the 
process can be lengthy, which introduces opportunities for both tissue contamination and 
degradation of key ECM molecules. In this study we report on the accelerated preparation of 
decellularized skeletal muscle (DSM) scaffolds using a infusion system and examine scaffold 
performance for the repair of VML injuries. The preparation of DSM scaffolds using infusion 
was dramatically accelerated. As the infusion rate (1% SDS) was increased from 0.1 to 1 and 
10ml/hr, the time needed to remove intracellular myoglobin and actin decreased from a 
maximum of 140±3hrs to 45±3hrs and 10±2hrs respectively. Although infusion appeared to 
remove cellular debris more aggressively, it did not significantly decrease the collagen or 
glycosaminoglycan composition of DSM samples when compared to un-infused controls. 
Infusion prepared DSM samples retained the aligned network structure and mechanical integrity 
of control samples. Infusion prepared DSM samples supported the attachment and in-vitro 
proliferation of myoblast cells and was well tolerated by the host when examined in-vivo. 
 
 
Keywords: decellularization, extracellular matrix, skeletal muscle, scaffold  
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A. Introduction 
 
 Our group is pursuing the development of biomaterials targeting the repair of damaged 
skeletal muscle tissue. Skeletal muscle has a strong capacity for repair, yet this capacity can be 
overwhelmed when damage is severe. Following mild injuries like strains and contusions, in 
which the myocytes are damaged but the underlying muscle structure and satellite cell 
population is preserved, regeneration is robust and surgical intervention is not indicated (Mauro 
1961, Hill, Wernig et al. 2003). However, when significant muscle volume is lost (trauma or 
surgical resection) the underlying structure and progenitor cell pool is absent and regeneration is 
poor. Termed volumetric muscle loss (VML), the bulk loss (>20%) of muscle tissue overwhelms 
the capacity for repair, leading to the formation of non-contractile scar tissue at the defect site 
and functional impairment for the patient (Terada, Takayama et al. 2001). The poor outcome 
following VML injury, motivates the need for a treatment option. A promising approach is 
restoration of the chemical and physical cues provided by the extracellular matrix (ECM).   
 To restore these cues, our group is exploring the use of ECM biomaterials derived from 
skeletal muscle. To improve the isolation of ECM from whole muscle tissue, a new 
decellularization approach was explored in this study. Commonly, the decellularization of whole 
tissues employs detergents (ex: sodium dodecyl sulfate) to lyse cell membranes and remove 
intracellular proteins, followed by DNAse/RNAse rinses to remove residual nucleic acids 
(Gilbert, Sellaro et al. 2006, Badylak, Freytes et al. 2009). The initial removal of intracellular 
proteins using detergents is typically a diffusion driven process, which for thicker tissues like 
skeletal muscle can be lengthy, requiring two weeks or more(Merritt, Cannon et al. 2010). This 
introduces opportunities for both tissue contamination and degradation of key ECM molecules. 
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In an effort to accelerate the process, the active delivery of detergents into whole organs has been 
achieved via vascular perfusion. The major inlets and outlets (arteries and veins) along with 
capillary networks are utilized to perfuse the entire organ. Perfusion decellularization has been 
used to produce whole organ scaffolds for the heart (Ott, Matthiesen et al. 2008), liver (Uygun, 
Soto-Gutierrez et al. 2010), lungs (Ott, Clippinger et al. 2010), kidneys (Sullivan, Mirmalek-Sani 
et al. 2012), and recently even entire limbs (Jank, Xiong et al. 2015).  
 Skeletal muscle tissue lacks the easily accessible major arteries and veins that are found 
in whole organs, motivating an alternative delivery approach.  The common utilization of 
intramuscular injection would suggest that fluid infusion through skeletal muscle might provide a 
viable delivery route for decellularization agents. Towards this end, our group has developed a 
scalable bench top infusion platform that uses a needle rather than the vascular system to deliver 
detergents deep into muscle tissue with the goal of accelerating the removal of intracellular 
proteins. The system also explores the distinct color change (red to white) that occurs within 
skeletal muscle tissue as myoglobin is removed during decellularization as a means to non-
invasively monitor the removal of intracellular proteins. The design/fabrication of the device, 
characterization of its performance, and measurement of infusion prepared decellularized 
skeletal muscle (DSM) properties are described in this report. Ultimately, we believe these 
materials could find utility as scaffolds for the repair of VML injuries. 
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B. Methods 
Absorbance Properties of Skeletal Muscle  
A visible light absorbance sweep was performed on rat (Sprague Dawley) gastrocnemius 
muscle samples in order to characterize the optical properties of whole and decellularized 
skeletal muscle. The changes in muscle absorbance properties that occur with decellularization 
would be utilized during the subsequent design of an optical monitoring approach. Rat muscle 
was selected based on its past use in muscle regeneration animal studies and the anticipated area 
of application for this device (Merritt, Hammers et al. 2010). All whole muscle tissues used in 
this study were collected from cadaveric animals that had been previously euthanized using 
methods approved by the University of Arkansas Institutional Animal Care and Use Committee 
(IACUC) approved study (protocol #12026). All tissues were stored at -20°C until required for 
testing. In preparation for testing, gastrocnemius muscle samples were dissected, and from each 
whole muscle sample a central core was harvested using a biopsy punch (diameter = 6mm) and 
trimmed to a thickness of 2mm. Cylindrical muscle sample cores were incubated in a 1% sodium 
dodecyl sulfate (SDS) solution (10mM Tris HCL) with agitation for 24 and 48 hours at room 
temperature following published protocols(Mirsadraee, Wilcox et al. 2006). Untreated muscle 
samples were maintained as controls (n=4 / sample group). At the prescribed time points (24, and 
48 hours) muscle core samples were loaded into 96 well plates (one sample per well) and a 
spectral sweep of tissue absorbance was measured (400-900nm, step size = 5nm) with the aid of 
a spectrophotometer (Synergy H1, BioTek, Winooski, VT). For comparison, the absorbance of 
myoglobin, an abundant intracellular skeletal muscle protein, was also characterized (0.1, 0.3, 
and 0.6% in phosphate buffered saline). Absorbance versus wavelength data for all muscle and 
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myoglobin samples were plotted and examined for the presence of decellularization sensitive 
absorbance features. 
 
Infusion Bioreactor Design and Fabrication 
The design goal was to combine continuous tissue infusion and real time optical 
monitoring into a single bench top device. The two primary components of the device are the 
muscle infusion units and optical detection collars with integrated data collection hardware and 
software. The infusion units, optical monitoring collars, and data collection hardware are housed 
within and mounted onto a custom fabricated (Replicator 2, MakerBot Industries, New York 
City, NY) two-piece enclosure (Figure 1). The enclosure was designed to accommodate four 
individual infusion units each capable of accommodating a single muscle tissue sample. The 
closure also isolates the optical monitoring collars from ambient light. Each of the four modular 
infusion units consists of a rigid acrylic cylinder (ID = 10mm; length = 40mm) that forms a 
translucent infusion chamber. The inlet and outlet of each chamber is enclosed by watertight 
ports fashioned with Leur lock style fittings and fabricated in acrylic with the aid of a 3-D printer 
(Objet 30, Objet, Israel). The inlet port incorporates a removable 26-ga stainless steel 
hypodermic needle (length = 20 mm). The needle is used to deliver solution into the interior of 
individual whole muscle samples. The flow of fluid into each infusion unit was controlled via a 
commercial multi-syringe pump (#552219, Harvard Apparatus, Holliston, MA) capable of 
delivering fluid to all four chambers over the range of flow rates (0.1 to 10ml/hr) that would be 
evaluated during device characterization. Waste decellularization solution is collected in a 
reservoir for disposal or evaluation. 
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The optical collar was fitted with a single light emitting diode (LED) producing a peak 
emittance centered at 535nm. Peak LED wavelength selection was motivated by the results of 
the previously described muscle optical property characterization. The light output of the LED is 
directed across the diameter of the optical collar. A light detecting resistor (LDR) was positioned 
opposite to the LED. The LDR converts light intensity in photons to resistance in ohms. The 
optical collar with integrated LED and LDR can be positioned along the length of the infusion 
unit. During infusion, the collar is positioned over the muscle sample, such that muscle tissue 
impedes the light path from the LED emitter to the LDR detector. Analog voltages collected 
from the LDR were converted to digital values using an 8-bit analog-to-digital converter (ADC) 
(Adafruit Industries, New York, NY). A miniaturized single board computer (Raspberry Pi 
Foundation, United Kingdom) was used to power the LEDs and to control collection of the 
digitized LDR voltage signal from the ADC. Custom designed software (Python) was created to 
collect the voltage data and log it to an online spreadsheet. Optical data was collected from the 
LDR every five minutes. The complete system, including syringe pump and flat screen monitor, 
occupies a 0.5m X 0.5m footprint, a space that is compatible with typical laboratory 
workbenches. 
 
Bioreactor Characterization 
For all device characterization testing, medial gastrocnemius muscle tissue was harvested 
from cadaveric Sprague Dawley rats and stored at -20°C until needed for testing. Prior to testing 
all muscles were thawed and rinsed briefly in DI water to remove any superficial blood or 
loosely adhered tissue. Whole muscle samples were loaded into infusion chambers, one muscle 
per chamber. The position of the muscle was adjusted until the needle tip was located at the mid-
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belly (thickest) region of the muscle. Based on static decellularization pilot testing and guided by 
published methods (Mirsadraee, Wilcox et al. 2006), muscle samples (n=4) were infused using a 
1% SDS solution at a flow rate of 1ml/hr while LDR output was recorded and plotted. Samples 
were collected when muscle optical properties (LDR output) were unchanged (<0.1% difference 
from the previous recording) for five continuous recordings (25 minutes). 
To examine the effectiveness of infusion treatment as a method for intracellular protein 
removal, representative infusion treated and untreated whole muscle samples were embedded in 
tissue freezing media (Triangle Biomedical Sciences, Durham, NC), sectioned at 8µm with a 
cryostat, and mounted onto glass microscope slides. Mounted sections were immune-reacted for 
the presence of myoglobin (rabbit IgG1, 1:500, Sigma, St. Louis, MO) and actin (phalloidin, 
1:40, Sigma, St. Louis, MO) followed by incubation with the appropriate fluorescently labeled 
secondary antibodies (Alexafluor, 1:500, Fisher Scientific). Sections were counterstained with 
the nuclear staining reagent DAPI, and then microscopically imaged (Ci-L, Nikon, Troy, NY). 
Digital images were captured, stored, and examined for the presence of intracellular proteins and 
nuclear remnants. 
To explore the influence of key infusion parameters (flow rate and SDS solution 
concentration) on myoglobin removal, medical gastrocnemius muscle samples were perfused at 
flow rates of either 0.1, 1, or 10ml/hr using SDS solutions at concentrations of 0.2% or 1%. A 
total of 6 parameter combinations were explored (n= 4/ parameter condition). Throughout 
infusion testing the optical properties of each muscle was measured and digitally logged every 5 
minutes. As previously described, the time at which intracellular protein removal was considered 
complete and samples were removed was recorded as the time at which sample optical properties 
were unchanged for five continuous recording.  
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 From the infusion data, the time to reach steady state optical properties (y) was modeled 
with a two factor (1: flow rate, 2: SDS concentration) regression model of the type 
   y =  b0 + b1x1 + b2x2 + b12x1x2          (1) 
The regression coefficients (bi) were solved for using commercially available data analysis 
software (JMP, SAS Institute, Cary, NC). From the model, the relationship of infusion time to 
each of the infusion parameters was calculated.  
 To determine whether infusion influenced the retention of key ECM molecules, the 
sulfated glycosaminoglycans (sGAG) concentration was quantified using a published 
procedure(Barbosa, Garcia et al. 2003). For comparison, control DSM samples were statically 
(non-infused) incubated in 1% SDS at room temperature with gentile agitation using rocker 
platform, for a duration of two weeks (Merritt, Cannon et al. 2010). All infusion and control 
samples were lyophilized and stored at -20°C until needed for analysis. To extract sGAG. 
lyophilized samples (n=4/sample group) were digested in a solution containing 50 µg/mL 
proteinase K in 100 mM K2HPO4 at a pH of 8.0 at 55ºC for 16 hours. The samples were then 
centrifuged and filtered to isolate tissue fragments. A 1,9-dimethylmethylene blue (DMMB) 
solution was added to produce an insoluble GAG-DMMB complex. The solution was 
centrifuged, the supernatant was removed, and the GAG-DMMB complex was dissolved with a 
decomplexation solution. The absorbance of the resulting solution was read at 656 nm with the 
aid of a microplate reader (Synergy H1, BioTek, Winooski, VT). Samples were tested in 
triplicate and compared against a standard curve to determine sGAG concentration. 
The collagen content of control and infusion samples (n=4/sample group) was quantified 
using a modified version of the hydroxyproline assay procedure reported by Edwards (Edwards 
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and O'Brien 1980). Briefly, all tissue samples were hydrolyzed in 6N HCl for 16-20 hours at 
115ºC, then cooled to room temperature and diluted 1:5 in distilled water. Hydrolyzed samples 
were mixed with a chloramine T solution (1:2) and incubated at room temperature for 20 
minutes. A dimethyl-aminobenzaldehyde assay solution was added (1:2) and the mixture was 
incubated at 60°C for 15 minutes to develop a red chromophore. Sample absorbance was read at 
570 nm using a microplate reader. Samples were tested in triplicate and compared against a 
standard curve to determine collagen concentration. To visualize and validate the retention of 
collagen within infusion prepared tissue, a representative sample was immunoreacted for the 
presence of collagen type I (mouse IgG1, 1:500, Sigma, St. Louis, MO) and type III (rabbit IgG1, 
1:1000, AbCam, UK) followed by incubation with the appropriate fluorescently labeled 
secondary antibodies (Alexafluor, 1:500, Fisher Scientific).   
 To explore the influence of infusion treatment on DSM physical properties, control and 
infusion (1% SDS for 12 hours at 10ml/hr) DSM sample (n=4/sample group) mechanical 
properties were measured with the aid of a uni-axial tensile tester (UStretch, CellScale, Ontario, 
Canada) using techniques familiar to our group (Wolchok, Brokopp et al. 2009, Lasher, Wolchok 
et al. 2010, Wolchok and Tresco 2010). Hydrated (PBS, pH=7.4) sample strips (12 mm X 3 mm) 
were deformed at a constant strain rate of 1%/s until failure using a 5N load cell while the load 
and displacement values were recorded. For each sample, engineering stress versus strain curves 
were generated from load and elongation data. Strain was determined using grip displacement 
values. From each curve the tangent modulus was calculated from a linear fit to the stress-strain 
curve. The ultimate strength was calculated as the peak stress achieved by each sample prior to 
failure. 
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 Additional control and infusion prepared DSM samples (n=4/sample groups) were 
embedded in tissue freezing medium and sectioned transversely (8um) with the aid of a cryostat. 
Sections were mounted onto glass slides, stained with hematoxylin and eosin (H&E) and 
microscopically imaged (100x). Three representative images from each sample were used to 
measure porosity (% open space) and network alignment (average orientation angle) using image 
analysis software (ImageJ) and guided by published techniques (Liu, Qu et al. 2008, Huang, Lee 
et al. 2010). For DSM sample orientation analysis, the direction of muscle contraction (long axis 
of the gastrocnemius muscle) was selected to correspond to an orientation angle of 0 degrees.  
  
In-Vitro and in-Vivo Biocompatibility 
 To create DSM samples for implantation, Sprague Dawley tibialis anterior (TA) muscle 
was infusion treated (1% SDS for 12 hours at 10ml/hr) using the previously described and 
characterized system. Following infusion treatment, samples were statically incubated overnight 
in a DNAse / RNAse solution (1kU/ml DNAse in a 10mM Tris-HCL buffer; 2.5mM MgCL2 + 
0.5mM CaCl2) and then incubated (8 hours) in a 1X penicillin/streptomycin solution to reduce 
the risk of infection. Samples were rinsed thoroughly (a total of six 24 hour wash steps) in PBS 
following each preparation step (Figure 2). Following completion of the entire decellularization 
protocol, the DNA concentration of representative DSM implants (n=3) was measured with the 
aid of a commercial quantification kit (Qubit, Fisher Scientific). DSM implants were lyophilized 
and stored at -20C until needed for implantation.  
 A direct contact assay was used to evaluate cellular attachment and proliferation upon 
infusion prepared DSM substrates. DSM material islands (diameter = 6mm) were created on 
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glass microscope slides. DSM islands were seeded with skeletal muscle myoblasts (L6, ATCC, 
Manassas, VA) at a density of 7K cells per island. Cell viability was evaluated at 3 and 7 days 
(n= 3 islands / time point) using calcein AM (Life Technologies). Three representative fields 
were imaged (100x) from each island and captured digitally. From the digital images, cell 
confluency (% surface coverage) was calculated at each time point with the aid of image analysis 
software (ImageJ). 
 In-vivo host response was examined using a dorsal subcutaneous implant site. In-vivo 
biocompatibility was assayed at short-term (4 weeks) and long-term (12 weeks) time points.  
Mature male Sprague Dawley rats (300+g) were used (Harlan, IN).  All surgical procedures were 
performed in accordance with protocols approved by the University of Arkansas Institutional 
Animal Care and Use Committee.  Anesthesia was induced using isoflurane (2-4%) in oxygen. 
The subcutaneous implant site was surgically exposed through a 2 cm left-right incision placed 2 
finger widths caudal to the scapulae. A subcutaneous pouch was created in each animal by blunt 
dissection. A single perfusion prepared DSM disk (6mm diameter X 1mm thick) was implanted 
into each pouch (Incisions were closed using surgical adhesive (VetBond, 3M).  Following 
surgery all animals were housed in the University of Arkansas Central Laboratory Animal 
Facility. At the prescribed time-points (4 and 12 weeks) all animals (n=3 / timepoint) were 
euthanized via inhalation of carbon dioxide. The implant site with surrounding soft tissue was 
harvested, fixed in 4% paraformaldehyde, paraffin embedded, sectioned (10um), and stained 
with H&E with the aid of the University of Arkansas Histological Core Facility.  Stained 
sections were imaged and examined for evidence of material degradation. 
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Statistics 
 All data is represented by the mean and standard deviation Comparisons between 
infusion flow rate and SDS concentration (time to stable optical properties, collagen, and sGAG 
analysis) were evaluated with a two-factor ANOVA. Post hoc comparisons were made using 
Tukey’s test. The effect of treatment (infusion version control) on alignment, porosity, and 
mechanical properties was evaluated using a two-way student’s t-test. A standard 0.05 level of 
significance was used for all statistical tests. 
 
C. Results 
Absorbance Properties of Skeletal Muscle  
 The absorbance sweeps collected from myoglobin solution samples (0.6%) were 
characterized by an observable peak centered at 505±4nm (Figure 2). As the myoglobin 
concentration was decreased to 0.3% and 0.1%, the absorbance peak heights decreased by 58% 
and 85% respectively and the peak profiles tended to broaden. The absorbance sweeps recorded 
from hydrated whole muscle samples were characterized by a more modest absorbance shoulder, 
which when compared to myoglobin was less pronounced and shifted modestly towards a higher 
wavelength (541±7nm). The whole muscle peak wavelength was positioned within the green 
region of the visible light spectrum. Following 24 hours of SDS incubation, the absorbance 
shoulder was still detectable but less pronounced. Visually, 24 hour muscle samples showed 
residual evidence of intracellular myoglobin (retention of a pinkish color), suggesting partial but 
still incomplete removal. After 48 hours of SDS treatment, the absorbance shoulder present in 
whole muscle samples was no longer detected and myoglobin was no longer visualized, as 
evidenced by a translucent appearance. Generally, the absorbance of skeletal muscle tissue at 
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541nm decreased as samples were progressively incubated in SDS, suggesting a valuable target 
wavelength for optical monitoring of intracellular myoglobin retention. 
 
Bioreactor Characterization 
 Muscle sample absorbance logs (LDR voltage versus time) were characterized by a 
progressive reduction in tissue absorbance (decreased LDR output voltage) with increased 
infusion time as more light (535nm) emitted by the LED was capable of transmitting through the 
muscle samples and reaching the LDR. Whole muscle samples transitioned from a characteristic 
red color to translucent during the infusion driven removal of intracellular proteins. (Figure 3). 
LDR voltage eventually reached a steady state minimum for all samples tested, which was 
defined for all subsequent tests as the time to myoglobin removal. Prior to infusion treatment, 
intracellular myoglobin, as well as actin and nuclear remnants where visible within whole muscle 
sections. Once the LDR had reached a steady minimum, identified as the time at which LDR 
output voltage was unchanged for 25 minutes, infusion treated muscle samples (n=4) were no 
longer immunoreactive to myoglobin or actin. Furthermore, although not treated with nucleases 
during the infusion process, DAPI positive nuclei could not be detected. Overall, the histological 
examination of infusion treated samples suggests that the LDR voltage minimum was an 
effective metric of intracellular myoglobin and actin removal. 
 The infusion solution flow rate and SDS concentration had a statistically significant 
effect on the removal of intracellular myoglobin (Figure 4). The average infusion time required 
to remove myoglobin, as measured by LDR voltage and further validated through histology, was 
shortened in response to increases to both flow rate and SDS concentration. Flow rate had a 
strong influence on myoglobin removal. The removal time decreased from a maximum of 
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143±8hrs at the lowest flow rate of 0.1 ml/hr (0.2%SDS) to 42±3hrs and 9±1hr as the flow rate 
was increased to 1ml/hour and 10ml/hour respectively. Increased SDS concentration had a 
significant but less dramatic influence when compared to flow rate. Increasing the SDS 
concentration from 0.2% to 1% shortened the time from 143±8hrs to 107±6 at the lowest flow 
rate tested (0.1ml/hr), a reduction of 24%. At higher flow rates (1 and 10ml/hr) the effect of SDS 
concentration on myoglobin removal was less pronounced, but still statistically significant. 
When viewed as a whole, the removal of intracellular myoglobin was more responsive to flow 
rate than SDS concentration, however the range of flow rates tested (100 fold difference between 
lowest and highest) was larger than the range of SDS concentrations tested (5 fold difference). 
From the data collected, the relationship of myoglobin removal time (in hours) to flow rate 
(ml/hr) and SDS concentration (%) was modeled (eq. 2). When plotted over the parameter ranges 
tested (Figure 4B & C), the model accurately describes the increased influence of flow rate on 
myoglobin removal time observed during benchtop testing. 
 
Time = 99 – 8.3 x [Flow] –18.0 x [SDS]  + 2.7 x (Flow - 0.6) x (SDS - 3.7)       (2) 
 
 Although SDS infusion accelerated the removal of intracellular myoglobin and actin, it 
did not significantly decrease collagen or sGAG concentration when compared to non-infused 
controls. No statistically significant differences in collagen or sGAG concentration were detected 
for any of the flow rates and SDS concentrations examined (Figure 5). All infusion treated 
collagen and GAG composition values were within 10% of control samples. Furthermore, trends 
indicating a relationship between ECM composition and infusion flow rate were not observed.  
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 Infusion decellularized samples retained the highly aligned network organization 
characteristic of skeletal muscle (Figure 6). The dominant orientation angle of DSM samples 
following infusion decellularization (7±6°) was not significantly different from controls (11±5°). 
Both infusion prepared and control samples were aligned in the direction of contraction 
(designated as 0°).  Control and infusion prepared samples were robust and easily tolerated 
handling and tensile testing. Stress versus strain curves for both materials were characterized by 
in initial toe-in region out to approximately 10-15% strain followed by a nearly linear (R2>0.9) 
increase is stress extending out to failure at approximately 100-125% for both infusion and 
control DSM samples. The average tangent modulus measured from the linear region extending 
from 20% (post toe-in) to material failure was 225±44kPa and 189±32kPa for infusion and 
control samples respectively. Average infusion prepared DSM sample elastic moduli was not 
significantly different from control samples. Similarly, average ultimate strength differences 
between infusion and control DSM materials were not statistically significant. 
 
In-Vitro and in-Vivo Biocompatibility 
Average infusion prepared DSM sample DNA content (2.9±0.6ng of DNA / mg of tissue) 
were well below the preferred implantation threshold (< 50-70ng/mg) reported by others (Zhang, 
He et al. 2009, Crapo, Gilbert et al. 2011). The DSM samples supported the attachment and in-
vitro proliferation of cultured myoblast cells. Viable cells were attached to all cell seeded DSM 
islands at both time points. Seventy-two hours after seeding, viable cells covered, on average, 
8±2% of the DSM sample surface (Figure 7). By seven days post seeding, average cell coverage 
increased to 60±6% of the DSM sample surface. Cells cultured on DSM materials appeared well 
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spread and expanded upon the DSM surface at a coverage rate of approximately 13% / day. The 
average cell coverage difference between day three and seven was statistically significant. 
 All implanted animals tolerated the subcutaneous implantation surgery well and reached 
the prescribed study endpoints without complications (n=4 / endpoint). At four weeks post 
implantation, DSM materials were well incorporated into the surrounding tissue and host cells 
had densely penetrated the material (Figure 8). While signs of active inflammation could be 
observed there were no signs of tissue necrosis or exudate (pus) accumulation at the implant site. 
The dense cellular penetration into the DSM material was suggestive of active remodeling of the 
implant site. The breakdown of whole DSM disks into smaller fragments was observed. There 
were no signs suggesting formation of a dense fibrous encapsulation layer surrounding DSM 
materials. By twelve weeks post implantation, DSM materials appeared fully degraded. No 
evidence of DSM material could be identified in any of the implanted animals, although some 
residual cellularity could be seen at the implant site.  
 
 
D. Discussion 
As chemical decellularization schemes continue to mature and gain acceptance, the 
development of effective delivery platforms deserves research investment. With that goal in 
mind, what was explored in this study is a device and method for the preparation of 
decellularized skeletal muscle tissue using a non-vascular infusion delivery method. Overall, the 
utilization of infusion on skeletal muscle samples was highly effective at accelerating the 
removal of intracellular proteins.  Specifically, with the aid of the infusion device, the time to 
clear rat lower limb gastrocnemius and TA muscles of intracellular proteins reduced from two 
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weeks to a short as 10 hours. This is a notable finding, and the first we are aware of that 
demonstrated the accelerated removal of cellular debris from bulk tissue samples using a non-
vascular infusion technique. It may be possible to translate this process to other tissues, 
particularly musculoskeletal tissues including, tendons (Lee, Lee et al. 2013), ligaments 
(Harrison and Gratzer 2005), cartilage (Sutherland, Beck et al. 2015), and menisci (Chen, Chen 
et al. 2015) in which vascular perfusion would be difficult. The time reduction is not just 
important from the standpoint of process efficiency, but also may help reduce the degradation of 
key ECM proteins that could occur with time throughout the decellularization process. The 
decellularization of tissue using SDS, the most common process, is typically performed at room 
temperature, and while the presence of SDS limits bacterial and fungal growth, the degradation 
of proteins that can occurs with time at room temperature is a concern (Pasella, Baralla et al. 
2013, Wang, Zhu et al. 2015). Shortening the amount of time tissue is exposed to room 
temperatures in aqueous solutions may reduce the degradation of key ECM proteins during 
decellularization and improve scaffold quality. 
 While the device described in this study was designed for the processing of small animal 
tissues for use in pre-clinical research, the future application of infusion to accelerate the 
preparation of human or large animal tissue for clinical applications is anticipated. Particularly 
since the complete removal of cellular debris from large skeletal muscle tissues, like the 
quadriceps which can be several centimeters thick, may be prohibitively lengthy using diffusion 
alone. It should also be noted that human skeletal muscle tissue is rarely if ever tissue banked, 
and therefore represents an untapped source for implantable human ECM. Device scale-up for 
the processing of larger muscle tissue will require design adaptations beyond just increasing the 
size of the chambers. The single needle infusion chambers developed in this study were designed 
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for the processing of single rat hind limb skeletal muscles. The volume of rat gastrocnemius and 
tibialis anterior muscles (1-2 cm3) was well suited to the delivery of decellularization solution via 
a single hypodermic needle. However, the processing of larger animal and potentially cadaveric 
human muscle samples for clinical applications would require modification to incorporate a 
multi-needle approach. While clearly more complex, our experience with the current single 
needle system suggests that expansion to a multi-needle system is achievable, and in fact the 
current system uses multiple needles to process muscle samples in parallel.  What remains 
unknown, is the optimal relationship between needle quantity, spacing, and tissue volume.  
Future bench top measurement and computer modeling of the relationship between time to 
decellularization and tissue volume would help determine ideal infusion needle density.  
 It should be possible to utilize lower SDS concentrations than those explored in this 
study, while still maintaining overnight to at most 1 day myoglobin removal times. At an 
infusion flow rate of 10ml/hr, the highest rate tested, a 5 fold decrease in SDS concentration 
(0.2% versus 1%) only increased the time from 7 to 9 hours suggesting an even lower SDS 
concentration might still be effective. A reduction in SDS concentration could be beneficial 
when one considers that removing SDS from tissue is challenging and the presence of residual 
SDS within implanted scaffolds can be cytotoxic (Cebotari, Tudorache et al. 2010). Furthermore, 
it is well established that exposure to SDS during the decellularization process can have a 
detrimental effect on tissue properties (Faulk, Carruthers et al. 2014). Eventually it may be 
beneficial to transition towards SDS-free decellularization approaches. If so, it seems reasonable 
to suggest that infusion could be utilized to decrease process duration for other solution based 
decellularization strategies, including SDS-free techniques that employ osmotic or physical 
means to disrupt cell membranes and liberate intracellular debris (Greco, Francis et al. 2015, 
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Xing, Yates et al. 2015). Alternatively, it may be possible to utilize a short SDS incubation step 
to initially lyse cells and bind intracellular proteins, followed by a longer SDS-free infusion step 
to wash away the intracellular debris and residual SDS. Whatever the method, it should be 
possible to utilize infusion as a means to minimize both the SDS concentration and exposure 
time during the decellularization process. 
 The monitoring of skeletal muscle optical properties provided a non-destructive real time 
means to evaluate decellularization progression. The histological results from this study suggest 
that the monitoring of muscle optical properties is a good indicator of intracellular myoglobin 
concentration. While we only looked at one additional intracellular protein (actin) it seems 
reasonable to speculate that if these two proteins were effectively removed other intracellular 
proteins were as well. One limitation is that optical monitoring of the type used the current 
device was designed to detect the progressive removal of the muscle specific intracellular protein 
myoglobin. The progressive removal of myoglobin produced an obvious shift in tissue 
appearance from red to clear, which could be detected in the visible region of the light spectrum 
using a low cost LED and LDR pairing. However, it has been suggested that removal of the 
nuclear debris is more crucial to implant performance than the intracellular proteins, suggesting 
that development of a means to monitor the removal DNA and RNA would be valuable (Gilbert, 
Sellaro et al. 2006). Unfortunately, the optical properties of muscle within the visible region are 
not affected by the removal of nuclear debris. As an adjunct to the currently monitoring 
approach, it may be possible to examine the optical properties of tissues at DNA/RNA sensitive 
wavelengths (260/280nm) to monitor the removal of nuclear debris, although using low cost 
LEDs to do so is not feasible.  
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 The co-delivery of muscle progenitor (satellite) cells in combination with ECM could 
also help stimulate a pro-regenerative environment following VML injury. The loss of muscle 
tissue following VML eliminates a substantial pool of progenitor cells. The remaining satellite 
cell population available for migration from surrounding healthy tissue may be inadequate, and 
therefore supplementation of the repair site with additional progenitor cells could enhance 
regeneration. Towards this end, the in-vitro seeding of ECM implants with progenitor cells has 
been shown to improve the restoration of peak contractile force (Merritt, Cannon et al. 2010, 
Corona, Ward et al. 2014). With this approach in mind, infusion flow could be used as a means 
to seed DSM implants with progenitor cells in preparation for implantation. Infusion could help 
distribute cells evenly throughout the DSM network, rather than densely at the surface as is 
generally observed following manual seeding(Kennedy, McCandless et al. 2011). Satellite cells 
are difficult to amass in great quantities, and can lose their regenerative capacity when expanded 
in vitro (Montarras, Morgan et al. 2005) so improving the efficiency of in-vitro progenitor cell 
delivery has value.  
 The average DSM modulus values measured in this study are similar in magnitude to 
other decellularized tissue scaffolds, including commercially available porcine intestinal and 
bladder tissue (Dahms, Piechota et al. 1998, Tottey, Johnson et al. 2011), as well as human facial 
DSM material (Wang, Johnson et al. 2013). The relationship between scaffold modulus and 
VML repair outcome has not been investigated, but in-vitro studies have shown that muscle 
progenitor cells sense and respond to substrate stiffness. Muscle progenitor cell myogenesis is 
significantly enhanced when the cells are grown on soft substrates like ECM and reduced on stiff 
substrates like tissue culture plastic (Rao, Grover et al. 2013, Morrissey, Cheng et al. 2015). 
Similar cell-substrate stiffness interactions have been noted for other cell types including 
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cardiomyocytes (Ribeiro, Ang et al. 2015). Furthermore, the robust mechanical properties of 
DSM and other ECM scaffolds facilitate attachment (suturing) to the surrounding healthy tissue 
during surgical VML repair. Surgical reattachment is clinically important, because it will enable 
the transfer of contractile force through the repair site during healing and regeneration. This is 
potentially critical, since force and substrate strain have been shown to enhance muscle 
progenitor cell myogenesis (Egusa, Kobayashi et al. 2013, Heher, Maleiner et al. 2015).  
 While the ideal VML repair scheme still awaits discovery, it appears the restoration of a 
pro-myogenic environment may require a multifactorial approach, combining biocompatible 
scaffolds, with progenitor cells, soluble myogenic signaling molecules, and postoperative 
rehabilitation (Aurora, Garg et al. 2014, Garvey, Russ et al. 2015). The accelerated removal of 
intracellular proteins from skeletal muscle tissues, without sacrificing chemical or physical 
properties, makes the infusion preparation platform described in this study an attractive scaffold 
preparation strategy. Furthermore pilot study biocompatibility testing suggesting that infusion 
prepared DSM both supported cell attachment and was well tolerated by the host, motivates 
further in-vivo examination using a peer accepted muscle regeneration animal model (Wu, 
Corona et al. 2012).  
 
E. Conclusions 
The key findings of this study suggest that: 
1) The delivery of SDS into skeletal muscle via infusion removed intracellular proteins 
including myoglobin and actin. 
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2) The monitoring of myoglobin absorbance was effective as an inexpensive means to non-
invasively monitor the progression of intracellular protein removal during 
decellularization. 
3) Infusion flow rate and SDS concentration could be adjusted to modulate the removal rate 
of intracellular proteins from whole muscle samples. 
4) Infusion did not reduce the collagen or sGAG composition of DSM scaffolds. 
5) Infusion did not influence the native network alignment or reduce the mechanical 
properties of DSM scaffolds.  
6) Infusion prepared material supported the attachment and proliferation of cells and was well 
tolerated by the host following subcutaneous implantation. 
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Figure Legend: 
 
Figure 1: The primary components of the as built device are the muscle infusion chambers and 
optical detection collars (A and B). SDS solution is delivered into muscle tissue via a 
hypodermic needle (not seen), infused through the muscle, and outflows to waste collection. 
Light produced by the LED travels across the chamber and though the muscle sample (B: dashed 
arrow) where it is detected and converted to a voltage output by the LDR. Infusion units, optical 
monitoring collars, and data collection hardware are housed within and mounted onto a custom 
fabricated enclosure (C and D). The enclosure was designed to accommodate four side-by-side 
decellularization units each capable of accommodating a single muscle tissue sample. LDR 
output voltage was converted to a digital signal (8-bit) and stored with the aid of integrated data 
collection hardware (Raspberry Pi) and software (Python). 
 
Figure 2: Representative visible light absorbance spectra for myoglobin solutions (A) and 
skeletal muscle tissue samples (B). The myoglobin absorbance peak (505±4nm) decreased as 
protein concentration was diluted from a high of 0.6% (in PBS) to a low of 0.1%. A less 
pronounced absorbance shoulder (541±7nm) was observed for whole muscle tissue samples. The 
absorbance shoulder for whole muscle samples (M) was similarly reduced as muscle samples 
were incubated in decellularization solution (1% SDS) for either 24 or 48 hours. 
 
Figure 3: Representative LDR voltage output (Vo) collected during whole muscle infusion 
treatment (A). The change in muscle color that occurs during infusion (removal of myoglobin) 
77 
 
permitted increased transmission of LED light (535nm) through the tissue, decreasing LDR 
resistance (A:inset). Decreased LDR resistance was measured and recorded as a change in output 
voltage (Vo). Prior to infusion, whole muscle tissue samples (B) were strongly reactive (D: left 
split) to antibodies/molecules directed against actin (red) myoglobin (green) and nuclei (blue). 
Following infusion treatment (C), recorded as the time to reach a stable output voltage minimum 
(A: arrow), actin, myoglobin and nuclei could not be detected in any of the samples tested (D: 
right split). Infusion prepared DSM samples retained the highly aligned structure of native 
muscle ECM (E) and were strongly immunoreactive to antibodies directed again collagen I and 
III (F & G). Unless noted, scale bar = 100um 
 
Figure 4: Both infusion flow rate (ml/hr) and SDS concentration (%) had a significant effect on 
removal of intracellular myoglobin (A). Values shown are mean+sd. Increases in both flow rate 
and SDS concentration significantly reduced the time needed to remove myoglobin. * = p<0.05; 
two factor ANOVA. The measured effects of flow (B) and concentration (C) were described 
using a linear model (see equation 2). Interaction effects between flow and concentration were 
not observed with the model or detected with ANOVA analysis. 
 
Figure 5: Infusion treatment did not significantly decrease the collagen or sGAG concentration 
of DSM samples when compared to non-infused controls. Values shown are mean+sd. p<0.05, 
two factor (flow and concentration) ANOVA. 
 
Figure 6: H&E stained longitudinal (A) sections prepared from infusion DSM samples (0° = 
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direction of muscle contraction). Representative infusion prepared DSM sample stress versus 
strain curve (B). When compared to controls, infusion treatment did not significantly influence 
(t-test P>0.05) DSM sample modulus, ultimate strength or alignment values (C). Values shown 
are mean+sd. Scale bar = 100um. 
 
Figure 7: DSM material substrates supported the in-vitro attachment and proliferation (A and B) 
of viable (calcein AM) myoblast cells. The percent surface coverage (B) was evaluated at 3 and 
7 days post cell seeding. Values shown are mean+sd. * p<0.05 compared to day 3, n=4/sample 
group, Scale bar = 100um 
 
Figure 8: DSM implants were prepared for implantation using the infusion device to first 
remove intracellular debris followed by incubation in a DNAse/RNAse solution to remove 
nuclear debris and penicillin/streptomycin to reduce the risk of implant infection. DSM samples 
were rinsed in PBS (a total of five 24-hour PBS washes) to remove residual SDS, nuclease, and 
antibiotic solutions (A). Stained (H&E) tissue sections collected four (B) and twelve weeks (C), 
following subcutaneous implantation of infusion prepared DSM scaffolds into Sprague Dawley 
rats. Infusion prepared DSM scaffold fragments were observed within the dorsal subcutaneous 
implantation site at 4 weeks (*) but were degraded by 12 weeks (**) in all animals examined 
(n=3/time point). Scale bar = 100µm 
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Abstract 
Skeletal muscle is capable of robust self-repair following mild trauma, yet in cases of 
traumatic volumetric muscle loss (VML), where more than 20% of a muscle’s mass is lost, this 
capacity is overwhelmed. Current autogenic whole muscle transfer techniques are imperfect, 
which has motivated the exploration of implantable scaffolding strategies.  In this study, the use 
of an allogeneic decellularized skeletal muscle (DSM) scaffold with and without the addition of 
minced muscle (MM) autograft tissue was explored as a repair strategy using a lower-limb VLM 
injury model (n=8 / sample group). We found that the repair of VML injuries using DSM+MM 
scaffolds significantly increased recovery of peak contractile force (81±3% of normal 
contralateral muscle) when compared to unrepaired VML controls (62±4%). Similar significant 
improvements were measured for restoration of muscle mass (88±3%) in response to DSM+MM 
repair when compared to unrepaired VML controls (79±3%). Histological findings revealed a 
marked decrease in collagen dense repair tissue formation both at and away from the implant site 
for DSM+MM repaired muscles. The addition of MM to DSM significantly increased MyoD 
expression, when compared to isolated DSM treatment (21 fold increase) and unrepaired VML 
(37 fold) controls. These findings support the further exploration of both DSM and MM as 
promising strategies for the repair of VML injury. 
 
Keywords: extracellular matrix; scaffold; regenerative medicine; orthopedics; musculoskeletal 
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A. Introduction 
 
Our group is exploring the development of strategies designed to treat volumetric muscle 
loss (VML) injuries. The substantial loss (>20%) of skeletal muscle tissue, either through trauma 
or surgical resection, appears to overwhelm the normal wound healing mechanisms that function 
effectively following minor muscle injuries (Terada, Takayama et al. 2001). It is generally 
recognized that to properly restore muscle function following VML injury, surgical intervention 
is required. Unfortunately, there are limited surgical options available to treat these clinically 
challenging VML injuries. The currently accepted surgical approach for the replacement of lost 
skeletal muscle is autologous muscle flap transfer (Vekris, Beris et al. 2008, Oishi and Ezaki 
2010, Terzis and Kostopoulos 2010). Although frequently successful, muscle flap transfer is a 
highly invasive procedure that introduces significant donor site morbidity and is therefore only 
rarely indicated. The search for a less invasive VML repair strategy warrants research 
investment. Towards this end, several groups, including ours, are exploring the development of 
engineered extracellular matrix (ECM) scaffolds targeting VML repair (Bian and Bursac 2009, 
Chiron, Tomczak et al. 2012, Juhas, Engelmayr et al. 2014, Hurd, Bhatti et al. 2015, Wilson, 
Terlouw et al. 2016).  
ECM scaffolds prepared from a variety of tissue sources have been utilized to repair a 
wide range of damaged tissues in animal models (Merritt, Cannon et al. 2010, Perniconi, Costa et 
al. 2011, Wolf, Daly et al. 2012, Corona, Ward et al. 2014) and recently in humans (Mase, Hsu et 
al. 2010, Sicari, Rubin et al. 2014). Within this class of tissue-derived ECM scaffolds, the 
application of decellularized skeletal muscle (DSM) as a repair strategy for VML injury has 
shown some promise (Merritt, Cannon et al. 2010, Wolf, Daly et al. 2012). The multi-molecular 
composition and highly aligned network architecture of DSM scaffolds are ideally suited for the 
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restoration of physical and chemical cues that are lost following VML injury. To improve the 
preparation of DSM scaffolds, our group has recently reported on a novel infusion method, 
which can accelerate the decellularization process, without compromising the physical, chemical, 
and biocompatibility properties (Kasukonis, Kim et al. 2016). Our goal is to explore the utility of 
these infusion prepared DSM scaffolds for the repair of VML injuries. Yet, the implantation of 
DSM scaffolds alone, particularly when explored in the lower extremity, appear to offer an 
incomplete intervention for the repair of VML injuries (Aurora, Roe et al. 2015), suggesting that 
other elements may be needed. 
Evidence suggests that restoration of a robust pro-myogenic environment may require a 
multifactorial approach, which includes combining ECM scaffolds with the appropriate 
progenitor cells. In animal studies, the co-delivery of muscle progenitor cells in combination 
with ECM scaffolds has been shown to improve functional recovery following VML injury when 
compared to ECM scaffold delivery alone (Merritt, Cannon et al. 2010, Corona, Ward et al. 
2014). The premise is that progenitor cells reestablish a needed pool of myogenic cells, which 
utilize the ECM implant as a substrate upon which to initiate regeneration of contractile 
myofibers.  Cellular co-delivery has yielded promising VML regenerative results, but does 
introduce increased clinical complexity, as it would require surgical collection and expansion of 
the patient’s progenitor cells prior to implantation. Our group is interested in exploring 
alternatives to in-vitro progenitor cell expansion and cultivation, with the aim of creating a single 
stage VML repair strategy. An attractive source of muscle progenitor cells is the collection and 
implantation of minced muscle (MM) autografts. MM contains several components, most 
notably satellite cells, necessary for the regeneration of skeletal muscle and has been shown to 
successfully regenerate damaged muscle tissue when examined in animal models of VML injury 
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(Corona, Garg et al. 2013, Ward, Ji et al. 2015).  Of particular interest to our group, MM 
autografts can be harvested from normal muscle tissue and seeded back into the injury site 
during a single stage surgical procedure. 
An anticipated roadblock to the clinical translation of MM autografts is the large volume 
of healthy muscle tissue that would be needed for grafting into a VML defect. At present the 
implantation of MM in quantities prepared using less than 50% of the VML defect mass has not 
been effective at restoring muscle function (Ward, Ji et al. 2015). While potentially less invasive 
than a full muscle flap transfer, the harvest of muscle tissue in volumes required to fill half the 
VML defect would still introduce significant donor site morbidity. Therefore, a repair strategy 
that reduces the amount of MM needed to stimulate functional muscle recovery would improve 
the clinical utility of MM autografts. Towards this end, our team is interested in exploring the co-
delivery of MM autografts with infusion prepared DSM scaffolds as a VML repair strategy. We 
suspect that the use of DSM material as a carrier material could reduce the amount of MM 
autograft needed to stimulate recovery following VML injury. Specifically, the study was 
designed to test the hypothesis that delivery of a DSM scaffold carrier combined with a MM 
autograft prepared using 25% of the defect mass (1/2 the current threshold for recovery) will 
significantly improve functional muscle recovery (increased contractile force) and myogenesis 
(increased MyoD expression) following hind limb VML injury in a small animal model.  
 
 
 
 
 
92 
 
B. Methods 
 
DSM Scaffold Preparation 
 To prepare DSM samples for implantation, whole tibialis anterior (TA) muscle was 
infusion decellularized using the previously reported (Kasukonis, Kim et al. 2016) infusion 
system (Figure 1). TA muscles were harvested from rats that had been euthanized at the 
completion of an unrelated study. Briefly, the wide mid-belly region of the TA muscle was 
positioned onto the infusion needle (27 gauge) and enclosed within a single decellularization 
chamber. Four TA muscles were prepared in parallel during each run. The TA samples were 
infused overnight (approximately 12 hours) with 1% SDS at a flow rate of 5mL/hr. Following 
infusion treatment, samples were incubated overnight in a DNAse solution (1kU/ml DNAse in a 
10mM Tris-HCL buffer; 2.5mM MgCL2 + 0.5mM CaCl2) and then incubated (8 hours) in a 1X 
penicillin/streptomycin solution to reduce the risk of infection. Samples were rinsed thoroughly 
(a total of six 24 hour wash steps) in PBS between each preparation step. Following completion 
of the entire decellularization protocol, the DNA concentration of representative DSM implants 
(n=4) was measured with the aid of a commercial quantification kit (Qubit, Fisher Scientific). 
DSM implants were lyophilized and stored at -20C until utilized for implantation.  
 
Animal Implantation 
 Fischer 344 rats (Harlan, Indianapolis, IN), weighing approximately 300-325g were used 
as the animal model for all implantation studies. Surgical procedures and DSM implant 
preparation methods were performed in accordance with protocols approved by the University of 
Arkansas IACUC (protocol #14044) and guided by published methods (Wu, Corona et al. 2012, 
Kim, Kasukonis et al. 2016).  Anesthesia was induced using isoflurane (1-3%) in oxygen. The 
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implant site was surgically exposed through a 1-2 cm incision running parallel to the tibia. The 
TA was identified and a partial thickness VML defect (8 mm diameter x 3 mm deep) was created 
using a sterile biopsy punch (Figure 2). The muscle tissue removed from the defect site was 
weighed and the weight was adjusted (increased only) if needed to ensure consistent defect mass 
across all animals (Average defect weight = 93.4 mg). Muscle defect mass values (20% of TA 
mass) were based on pilot study TA muscle mass measurements (average TA mass = 470±17 
mg). Muscle defect plugs were retained for use as MM autografts. Animals were randomly 
assigned to one of three treatment groups (n=8 animals / treatment groups) 
Group 1: Unrepaired VML defect 
Group 2: VML defect repaired with an isolated DSM scaffold 
Group 3: VML defect repaired with a DSM scaffold supplemented with MM autograft 
tissue (25% of the VML defect mass) 
 
  A single infusion-prepared DSM scaffold was cut to size (average DSM mass = 4.9±0.7 
mg) using surgical scissors and implanted into freshly prepared VML defects (Group 2). For 
animals in the DSM+MM experimental group (Group 3), 25% of the defect muscle plug was 
hand minced into a loose paste using a scalpel and scissors until MM fragments larger than 
~1mm3 could not be visually detected. The white DSM scaffolds were manually rolled in the 
pink MM autograft paste until all surfaces were visibly coated. DSM+MM constructs were 
implanted into the VML defect. Care was taken to ensure that DSM implant network alignment 
was matched to TA alignment. Unrepaired VML defects (group 1) served as negative controls 
(n=8/ experimental group). The contralateral limb was left untreated to serve as an internal 
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comparative control. To remain consistent with previous MM repair techniques, the DSM 
scaffolds were sized to fill, but were not sutured to the surrounding muscle tissue. The deeper 
fascia and surface skin layers were separately closed using an interrupted stich with a 5-0 
absorbable suture (Vicryl, Ethicon, Summerville, MA). A single surgeon (BK) performed all 
implantation procedures including the preparation of MM autografts. Postoperative analgesia 
consisted of 0.1mg/kg buprenorphine administered subcutaneously via injection twice daily for 
two days. Animals also had access to the anti-inflammatory medication (Carprofen) via a single 
dietary gel cup (Medigel CPF, ClearH2O, Westbrook, ME) added to each cage following 
surgery. Animal consumption of the gel was voluntary and any uneaten gel was removed from 
the cage at 1-week post surgery. Following surgery, animals were housed in standard-sized rat 
cages with unrestricted movement. The animals were allowed to bear weight on the operative 
extremity as tolerated. All animals were housed for a 12-week recovery period. 
 
Contractile Force Measurement 
 At the completion of the 12 week recovery period, the peak tetanic contractile force was 
measured in situ as described in Corona et al (Corona, Garg et al. 2013). Animals were 
anesthetized and the lower limb was stabilized at 90° of knee flexion (tibia parallel to the 
benchtop) using a custom made alignment jig (Supplemental Figure 1). The ankle was flexed to 
90° and the foot was secured (surgical tape) to the lever arm of a dual-mode muscle lever 
systems (Aurora Scientific, Ontario, Canada,). To isolate the contribution of the TA during force 
measurement, distal tenotomies were performed on the extensor digitorum longus (EDL) and 
extensor halluces longus (EHL). TA peak isometric tetanic force was measured by stimulating 
the peroneal nerve with the aid of a physiological stimulator (Grass; S88). Optimal voltage (2 – 5 
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V) was determined using a series of tetanic contractions (150Hz, 0.1 ms pulse width, 400 ms 
train). Average peak tetanic force for each animal was calculated from an average of 5 
contractions. All contractions were separated by one minute of rest. Raw peak tetanic contractile 
force (N) was recorded from both the treated and contralateral control limb of each animal and 
normalized to animal weight (N/kg). The weight normalized force data (N/kg) is reported in the 
results section. At the conclusion of electrophysiological testing, all animals were euthanized 
through carbon dioxide inhalation in accordance with guidelines provided by the 2013 AVMA 
Panel on Euthanasia of Animals.  
 
Tissue Histology 
 Unrepaired and repaired TA muscles along with contralateral untreated TA muscles were 
harvested and trimmed to remove the periosteum and tendon. EDL muscles were also collected 
and weighed for comparison between treated and contralateral control limbs. Muscles were 
rinsed in sterile PBS, dabbed dry, and then weighed. Muscles were then immediately flash frozen 
in liquid nitrogen cooled isopentane. Frozen TA tissue samples (n=4/experimental group) were 
sectioned (7μm) transversely through the mid-portion of the defect site with the aid of a cryostat. 
Sections were mounted onto microscopic slides and immuno-stained for the presence of myosin 
heavy chain (αMHC, 1:40, Iowa Hybridoma Bank), a muscle specific protein marker, collagen 
type I (αColI, 1:750, Sigma), collagen type III (αColIII, 1:000, Abcam) or laminin 1 (αLn, 500:1, 
Sigma) followed by incubation in the appropriate fluorescently labeled secondary antibodies 
(Alexfluor, 500:1, Life Technologies). Additional tissue sections were stained using a 
commercial Masson’s Trichrome kit following manufacturers guidelines (Sigma). All sections 
were mounted onto microscope slides and digitally imaged. Treated sections were evaluated for 
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myofiber formation and organization as well as the formation and extent of repair tissue 
formation for comparison to untreated contralateral muscle tissue sections.  
Measures of collagen type I accumulation, a potential indicator of diffuse muscle fibrosis, 
in tissue regions away from the VML defect area were estimated from collagen I 
immunoreactivity and guided by published methods (Bedair, Liu et al. 2007). Tissue 
immunoreactivity to collagen I was calculated from fluorescent microscopic images (200X) 
using image analysis software (Image J). A total of three non-consecutive tissue sections 
collected from three representative animals (n=3/treatment group) were used for all calculations. 
From each section, three images were obtained from the posterior half of the TA muscle at 
regions located distant to (> 3 mm) the anterior defect/repair site. A total of nine images were 
analyzed for each animal. All images were converted to 8-bit, grey scale, and uniformly 
thresholded across all samples to isolate collagen type I positive tissue regions. From these 
images the percent collagen type I positive tissue area was calculated for all treatment and 
control sections.  
 
MyoD and ECM Gene Expression  
Real-time PCR was performed using the protocol described in Washington et al. 
(Washington, Brown et al. 2013) Tissue samples (approximately 30mg) collected from the 
defect/repair site (n=4/sample group) were homogenized with Trizol (Ambion, Carlsbad, CA), 
chloroform (Sigma Aldrich, St. Louis, MO), and treated with DNase (Invitrogen, Carlsbad, CA). 
RNA was extracted using the RNeasy kit (Invitrogen, Carlsbad, CA). RNA concentration and 
purity was determined by UV spectrophotometry. RNA with a 260-to-280-nm ratio ≥ 1.8 was 
used for subsequent analysis. cDNA was reverse transcribed from 1 µg of total RNA using the 
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Superscript Vilo cDNA synthesis kit (Life Technologies, Carlsbad, CA, USA). cDNA was 
amplified in a 25 µL reaction containing appropriate primer pairs and TaqMan Universal 
Mastermix (Applied Biosystems, Grand Island, NY). Commercially available TAQMAN primers 
(Invitrogen, Carlsbad, CA) for MyoD, Timp-1, Collagen I, Collagen III, TGF-β1, MMP2, and 
18s ribosomal housekeeping were used to quantify the expression of desired matrix and matrix 
regulatory genes. Samples were incubated at 95°C for 4 minutes, followed by 40 cycles of 
denaturation, annealing, and elongation at 95°C, 55°C, and 72°C, respectively. TaqMan 
fluorescence was measured at the end of the extension step each cycle.  Experimental group 
samples were normalized to 18s and then referenced to the contralateral normal limb. Gene 
expression levels are reported as fold change using the 2-(Δ ΔCt) method. 
 
Data Analysis 
 Based on an a priori power analysis, the implantation of 8 animals per group was 
determined to be sufficient to detect a 15% increase in contractile force between treatment and 
control animals. This level of detection was designed to detect physiologically relevant and 
functionally meaningful increases is muscle contractile force. Pilot testing mean and standard 
deviation contractile force values (2.10±0.15 N/kg) collected from intact TA muscle samples 
were used. All data are represented by the mean and standard error unless noted. Data were 
tested for normality using the Shapiro-Wilk Test. Comparisons between treatment groups (VML, 
DSM, and DSM+MM) for each of the outcome measures (peak force, muscle mass, collagen I % 
area, and gene expression) were evaluated with a one-way ANOVA using a commercial 
statistical software package (JMP). Post hoc comparisons were made using Tukey’s test. A 
standard 0.05 level of significance was used for all statistical tests. 
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C. Results 
 
Average DSM sample DNA content (1.0±0.1ng of DNA / mg of tissue) was well below 
the preferred implantation threshold (< 50-70ng/mg) reported by others (Zhang, He et al. 2009, 
Crapo, Gilbert et al. 2011). Isolated DSM implantation took approximately 30 minutes to 
complete. The addition of MM preparation and coating steps added approximately 10 minutes 
the procedure. Both DSM and DSM+MM treatment groups tolerated the implantation surgery 
well. All animals gained weight throughout the observation period at a rate (8.3±0.5 and 8.5±0.3 
grams/week) that was not significantly different from un-repaired VML defect animals (8.8±0.6 
grams/week). There were no signs of post-surgical infection. At one week post-implantation, all 
animals were fully ambulatory with no noticeable gait differences between groups. Carprofen 
dietary gel cups were typically consumed within the first 3 days of surgery (effective dosage 
(5/mg/kg/day). All animals reached the 12-week study end point without complications.  
After the 12-week recovery period, bilateral measurements of the isometric TA muscle 
tetanic contractile force were obtained. Tetanic contraction plots for all muscles were 
characterized by a sharp rise in force, followed by a plateau at the peak force, and then a return 
to a no force resting state (Figure 3). The average peak tetanic force produced by normal 
contralateral TA muscles was 2.0±0.1 N/kg when normalized to animal mass. Following VML 
injury without repair, the average peak tetanic force dropped to 1.4±0.1 N/kg, which is 
equivalent to 62±3% of normal contralateral TA muscles values, a statistically significant 
reduction (p<0.05). Following repair with isolated DSM, TA muscles produced an average 
contractile force of 1.5±0.1 N/kg, which represents a 17% recovery of the peak force when 
compared to the unrepaired VML muscle group. Although elevated, the peak force recovery 
following isolated DSM repair was not statistically significant when compared to the unrepaired 
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VML group. In response to repair with combined DSM+MM, the average peak tetanic force 
increased to 1.7±0.2N/kg, which represents a 50% recovery in force production when compared 
to unrepaired VML values. The recovery of peak tetanic force following DSM+MM repair was 
statistically significant when compared to the unrepaired VML group (p<0.05).  
For all muscles harvested there was no evidence of implant site infection or gross 
deformity at the treatment site following 12 weeks of recovery. Generally, each of the treatment 
group muscles appeared smaller than contralateral normal muscle and the defect site could often 
be identified grossly (Figure 4). The muscles repaired with DSM and DSM+MM appeared to 
have less fibrosis at the treatment site and less atrophy overall when compared to the unrepaired 
muscles, but still had a less organized surface morphology at the treatment site when compared 
to the ordered striations of normal muscle. Untreated VML sample animals had a body weight 
normalized average TA mass of 1.27±0.1 g/kg, which is 79±3% of the contralateral normal TA 
mass. TA muscle defects repaired with isolated DSM had an average normalized mass of 
1.33±0.1g/kg, which is 82±3% of contralateral normal muscle mass and represents a 14% 
recovery in muscle mass when compared to the unrepaired VML group. The group of TA 
muscles repaired with combined DSM+MM had an average mass of 1.40±0.1g/kg, which is 
equivalent to 88±3% of contralateral normal values. DSM+MM muscle mass was significantly 
increased when compared to the unrepaired VML treatment group  (p<0.05), but not 
significantly greater than the isolated DSM repair group. On average, DSM+MM treated muscles 
recovered 43% of the muscle mass lost following VML injury (79% vs. 88% of normal).  Of 
note, EDL muscles collected from the treated limb were on average larger than contralateral 
EDL muscles for each treatment group (VML, DSM, and DSM+MM), suggesting compensatory 
hypertrophy.  
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At 12 weeks post surgery, the defect sites were detectable in histological sections 
prepared from all treatment groups. Transverse histological images of the defect sites for all 
treatment groups were characterized by the accumulation of repair tissue at the muscle surface 
(Figure 5).  Unrepaired VML and isolated DSM repair defect site tissues were strongly 
immunoreactive to collagen type I, suggesting collagen-enriched connective tissue deposition 
(fibrosis) at the defect/repair site. Additional ECM proteins, including fibronectin, collagen type 
III, and laminin were each detected within the repair tissue (Figure 6). While the general 
composition of the repair tissue layer was similar across all treatment groups, the size/thickness 
of the layer was notably different between groups. Specifically, it was generally noted that the 
repair tissue layer observed in DSM+MM treated samples layer was distinctly thinner than both 
unrepaired VML and isolated DSM repair groups. The repair layer was often difficult to locate in 
many tissue sections. For all treatment groups, MHC positive muscle fibers were present up to 
the border of the repair layer, but were not observed within the layer itself. For all groups, the 
collagen dense repair layer was notably thinner (50-500um) than the original VML defect 
(3mm), suggesting atrophy of the transected muscle tissue proximal and distal to the defect site. 
The Masson’s trichrome staining revealed signs of increased collagen deposition (blue 
staining) around muscle fibers in tissue regions that extended beyond the defect site for both 
unrepaired VML and isolated DSM repaired tissue sections. Similar qualitative increases in 
collagen staining were not observed in DSM+MM Masson’s stained tissue sections. Subsequent 
quantitative analysis of collagen type I immunoreactivity supported the Masson’s Trichorme 
observations. When measured using tissue sections prepared from normal contralateral skeletal 
muscle samples, collagen I positive immunostaining regions occupied, on average, 6.2±1.3% of 
the total tissue section area (Figure 7). For sections prepared from unrepaired VML and isolated 
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DSM repaired samples the percent surface area increased to 6.5±0.8%, and 8.6±0.5%, of the total 
surface area respectively. The elevated collagen type I area values detected following isolated 
DSM repair represents a 33% increase over normal tissue values. Alternatively, DSM+MM 
repair group collagen I percent area (5.4±0.7%) was below all other groups including normal 
muscle. On average, DSM+MM treated collagen I percent area values were 12% and 37% below 
VML and isolated DSM repair values respectively. The difference between DSM+MM and 
isolated DSM values was statistically significant. 
Six key genes associated with ECM structural proteins (collagen I and III), ECM 
regulatory cytokines (TGF-β1, MMP2, and TIMP-1) and myogenesis (MyoD) were examined 
with the aid of rt-PCR. (Figure 8). Muscle tissue samples collected from both unrepaired VML 
defect sites and isolated DSM repair sites produced approximately one tenth the relative 
expression of MyoD when compared to normal contralateral TA muscle, with fold changes of 
0.08±0.04 and 0.14±0.06 respectively. Alternatively, the DSM+MM repaired muscle group 
produced a statistically significant increase (p<0.05) in the expression of MyoD with a fold 
change of 2.95±0.47 when compared to normal TA muscle samples. Analysis of tissue collected 
from both the VML and isolated DSM repair groups revealed modestly increased structural and 
regulatory ECM gene expression values when compared to normal tissue controls. Collagen type 
I expression levels measured from unrepaired VML, and isolated DSM, muscle samples were 
1.55±0.14 and 2.60±0.89 of normal muscle respectively. The expression pattern for each of the 
ECM regulatory genes followed a similar trend; MMP2, TGF-β, and TIMP-1 expression was 
typically doubled within VML and Isolated DSM repair tissue samples. Expression levels for 
each of the structural and regulatory ECM genes were markedly increased in response to 
combined DSM+MM repair. The expression level for DSM+MM repaired samples exceeded 
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both the VML and isolated DSM treatment groups by statistically significant margins for each of 
the genes examined (p<0.05) and were generally an order or magnitude greater than normal 
contralateral TA tissue expression values. 
The gene expression ratios for each of the five ECM genes to the MyoD gene (e.g. Col 
I:MyoD) were calculated across all treatment groups for comparison to normal muscle (Figure 
9). Generally, normal muscle samples produced ECM to MyoD expression ratios that clustered 
around a value of 13 and ranged from a low of 10±5  (Col1/MyoD) to a high of 16±8 
(Col3/MyoD). Unrepaired VML and isolated DSM repair gene expression ratios were all 
significantly elevated (3 to 4 fold) in comparison to normal muscle values, and clustered between 
values of 30 and 50. Alternatively, DSM+MM gene expression values were generally lower than 
normal muscle values ranging from a low of 4±2 (TGFB1;MyoD) to a high of 11±5 
(Col1/MyoD). DSM+MM gene expression ratios calculated for Col I and Col III to MyoD were 
closely matched to normal muscle values and represented the only ratio values across all 
treatment groups that were not significantly different from normal muscle. The main outcome 
measures for each of the treatment groups are summarized in Table 1. 
 
 
D. Discussion 
 
The key findings from this study suggest that the use of an acellular DSM scaffold 
improved functional recovery from a VML injury and the addition of a MM paste further 
enhanced regeneration. Specifically, the combination of a DSM scaffold with MM paste restored 
approximately half the contractile force that was lost to VML injury, a finding that was 
consistent with the measured increases in TA muscle weight following DSM+MM repair. 
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Secondary findings suggest that the presence of the MM increases myogenesis, indirectly 
assessed through MyoD expression analysis, and decreased the accumulation of collagen 
enriched repair tissue at the site of the defect. When taken together the electrophysiological, 
histological, and gene expression data provided evidence suggesting that the addition of MM to a 
DSM graft can be utilized to improve muscle regeneration following VML injury.  
The infusion bioreactor utilized in this project is a new approach developed by our lab to 
accelerate muscle tissue decellularization. Although perfusion decellularization has been 
performed on the entire forelimb of a rat (Jank, Xiong et al. 2015) and whole organs, such as the 
liver (Uygun, Soto-Gutierrez et al. 2010), heart (Ott, Matthiesen et al. 2008), kidneys (Sullivan, 
Mirmalek-Sani et al. 2012), and lungs (Ott, Clippinger et al. 2010), muscle tissue lacks the easily 
accessible vasculature needed for perfusion, motivating a different approach whereby 
decellularization solution was infused into the bulk tissue via a needle. In our recently published 
work, it was demonstrated that DSM scaffolds produced through infusion decellularization retain 
the composition, mechanics, and architecture of native muscle ECM. The major advantage of our 
infusion device is that it produces a decellularized scaffold in under 10 hours compared to 
standard diffusion based (incubation with agitation) methods that can take up to two weeks for a 
similarly sized muscle (Merritt, Cannon et al. 2010). Moving forward, a single needle system 
could be scaled up to create a multi-needle infusion device capable of decellularizing bulkier 
muscle samples needed for large animal models or eventually human tissue for clinical studies. 
Furthermore, while we currently don’t use the infusion process during the DNAse and rinse 
steps, we could certainly anticipate utilizing the system to accelerate all process steps. 
Ultimately, we believe the infusion prepared DSM scaffolds are an appropriate material from 
which to explore VML repair strategies. 
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The MM co-delivery with DSM was initially motivated by findings reported by Corona 
et al (Corona, Garg et al. 2013). The harvest of MM autografts in a clinical setting makes it an 
intriguing source of implantable satellite cells for co-delivery with DSM. Rather than utilizing 
satellite cells which are first harvested, purified, expanded, and then ultimately implanted using a 
two stage surgical strategy, MM can be acquired and delivered along with allogeneic DSM in a 
single stage procedure. While a single procedure strategy may simplify surgical planning, we 
clearly recognize that the MM volume (25% of the defect mass) utilized in this study, although 
far less than the full defect size, would still produce harvest challenges and donor site morbidity 
concerns. To minimize morbidity, it may be possible to collect subcritical muscle biopsies from 
contralateral muscle sources.  Ultimately, the use of a MM grafting may have the greatest utility 
for the repair of smaller muscles like those of the face (Cardenas-Mejia, Covarrubias-Ramirez et 
al. 2015) and hands (Lin, Zhu et al. 2012) where a therapeutic volume of MM muscle could be 
harvested from the larger muscle of the lower limbs in a manner consistent with the harvest or 
the middle third of the patellar tendon during anterior cruciate ligament reconstruction (McGuire 
and Wolchok 1997). 
The encouraging signs of functional regeneration that were observed in response to 
minced muscle implantation hint at additional cellular implantation factors that may enhance 
myogenesis within DSM implants. Specifically, the use of minced muscle may do more to 
enhance muscle regeneration than simply increase the available pool of satellite cells at the 
injury site. Following muscle sprains and strains, the presence of injured myocytes within the 
wound site provides pro-regenerative cues. Specifically, it is understood that signaling cascades 
initiated in response to myofiber injury activate inflammatory and myogenic cells that stimulate 
the muscle repair process during the essential early phases of regeneration (McClung, Davis et 
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al. 2007). Inclusion of the signaling cues initiated by myofibers injury may provide opportunities 
for novel repair strategies. These cues could be provided directly through seeding of DSM 
scaffolds with myofibers (minced muscle) as was examined in this study, or alternatively by 
identifying the key chemical signals produced in response to myofiber injury and engineering 
them into a biomimetic repair strategy. 
 The selection of a MM graft prepared using 25% of the VML defect mass was motivated 
by Corona’s recent work showing that MM seeded in a collagen hydrogel did not effectively 
repair VML injury when the mass of MM was prepared using less than 50% of the tissue 
collected from the muscle defect (Ward, Ji et al. 2015). Others have utilized the entire defect to 
produce significant regenerative results (Corona, Garg et al. 2013). By exploring the use of a 
25% volume MM graft, the low end of what has been explored by others thus far, we hoped to 
determine whether DSM scaffolds could improve the muscle regenerative performance of MM 
autografts beyond that which has been achieved to date.  The lack of an isolated MM 
implantation controls group was a regrettable shortcoming to this study. It would have been 
valuable to know the contribution of the MM graft, and help elucidate whether the improved 
functional recovery measured following combined DSM+MM delivery was simply additive or 
whether there were interaction effects that enhanced regenerative performance when combined. 
Yet, while the effect of isolated MM was not evaluated in this study, what is clear, is two 
strategies that showed modest effectiveness when used separately (isolated DSM or <50% MM 
grafting) stimulated significant functional muscle recovery when used in combination, 
suggesting to us that infusion prepared DSM material is a MM carrier scaffold worthy of 
continued investigation.  
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 Towards this end, an improved understanding of the interactions between the MM paste 
and DSM scaffold is warranted. In particular, it would be of interest to know whether the DSM 
scaffolds are serving as simply a carrier material for the delivery of satellite cells, or whether the 
scaffold creates a pro-myogenic environment that enhances satellite cell expansion. DSM+MM 
interactions could be explored over the short term using in-vitro models, or in-vivo utilizing 
earlier time points. The longer 12-week time point used in this study, while appropriate for the 
detection of force recovery, missed the key regenerative events that occur during early wound 
healing. Research suggests that a one-week time point may be more appropriate for the detection 
of regenerative satellite cell activity (Tian, Jiang et al. 2016).  
 The increased effectiveness of the DSM+MM scaffold when compared to the collagen 
hydrogel + MM examined by Corona could potentially be attributed to the architecture of the 
DSM scaffold. Scaffolds composed of decellularized skeletal muscle, including the infusion 
prepared scaffolds explored in this study, are unique because they retain the parallel alignment of 
the native muscle from which they were obtained (Hinds, Bian et al. 2011). We, as well as 
others, anticipate that scaffolds with muscle mimetic network alignment will improve muscle 
regeneration by providing the appropriate topographical cues during healing (Bian and Bursac 
2009, Lam, Huang et al. 2009). In whole muscle, ECM surrounds and supports multinucleated 
myofibers which are highly aligned in the direction of muscle contraction. The individual fibers 
range from 5 to 100 um in diameter, and can be as long as several centimeters (Maier and 
Bornemann 1999). During implantation we were careful to orient the DSM scaffolds in the 
direction of TA contraction. In-vitro models indicate that muscle progenitor cells utilize 
alignment cues during myogenesis (Jana, Leung et al. 2014, Patel, Mukundan et al. 2016). 
Similar alignment-sensitive responses have been reported for other cells, including cardiac 
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muscle and tendons (English, Azeem et al. 2015, Morez, Noseda et al. 2015). Yet, while the 
many in-vitro alignment studies support the motivation of aligned regenerative scaffolds, we 
recognize that in-vivo evidence indicating that scaffold alignment is critical to muscle implant 
success does not yet exist. The lack of in-vivo data supporting the importance of scaffold 
alignment in muscle regenerative therapies would appear to motivate future studies. 
VML repair with DSM+MM dramatically increased gene expression for each of the 
structural and regulatory ECM genes explored in this study. However, the histological 
appearance of defect/repair site tissue for both VML and isolated DSM repair groups would 
suggest that ECM deposition and gene expression should be increased in these groups when 
compared to the DSM+MM group. We suspect that ECM gene expression levels for both VML 
and isolated DSM groups were elevated during earlier time points; an expression pattern that is 
consistent with muscle fibrosis (Davis, Korn et al. 2015). Once a stable fibrotic scar was formed, 
the genes returned to the lower expression values we measured at 12 weeks. It is also important 
to note that the collagen I immunoreactivity and PCR analysis were conducted on samples taken 
from different tissue regions. Collagen immunoreactivity was assessed within tissue regions 
located distant to the repair/defect site, while the tissue used for PCR analysis was collected from 
the repair site. As a result, the collagen immunoreactivity measures are likely an indicator of 
tissue wide ECM adaptation to differences in force generation and transmission between 
treatment groups (Hjorth, Norheim et al. 2015), while the PCR results are indicative of the 
regenerative and remodeling processes occurring at the site of repair.  
The PCR data suggests that the addition of MM to DSM scaffolds prolongs myogenesis 
and ECM production at the repair site following VML injury repair. The increased expression of 
ECM related genes and MyoD at 12 weeks could be indicative of active remodeling and 
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adaptation at the defect site in response to muscle activity (Hyldahl, Nelson et al. 2015). 
Alternatively, the prolonged upregulation of ECM genes at 12 weeks could be indicative of 
ongoing fibrosis (Mann, Perdiguero et al. 2011). To determine whether the expression patterns 
we observed at 12-weeks are beneficial or pathological, longer recovery time points may need to 
be explored to determine whether contractile recovery is maintained. Additionally, it may be of 
interest to explore gene expression profiles both within and away from the repair site to gain a 
better understanding of muscle wide responses to each repair scheme. 
We explored the ratio of the relative gene expression for each of the ECM genes to 
MyoD in order to elucidate differences that may exist between normal muscle homeostasis and 
each of the treatment groups. The relationships between key repair genes may provide additional 
insights into the repair process, and in fact gene expression ratios have been utilized to examine 
tissue healing trends in musculoskeletal tissues including bone (Chow, Leung et al. 2014) and 
ligament (Canseco, Kojima et al. 2012). In this study, normal TA muscle tissue ratios 
(ECM:MyoD) ranged between 10 and 15 for each of the ECM genes measured. Repair strategies 
that increase expression ratios away from normal TA values might suggest a shift in the repair 
process towards increased ECM production and/or decreased myogenesis. In contrast, repair 
strategies that cause expression ratios to fall below normal TA values might alternatively suggest 
a shift towards decreased ECM production and/or increased myogenesis. With that hypothesis in 
mind, the DSM+MM repaired muscle groups expressed ratios that were at or below normal 
muscle for each of the genes tested. Conversely, muscles that received VML defects and those 
that were repaired with isolated DSM had ratios ranging from 32.9-51.5 and 28.6-38.1 
respectively. Potentially, these and other gene expression ratios could be used to evaluate VML 
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repair strategies in future animal models, and may provide insights into treatment strategies that 
target gene pairs. 
 The co-delivery of DSM with MM restored approximately half of the peak contractile 
force lost following VML injury (81% versus 62%). The question then remains; what additional 
strategies could be utilized to restore the last twenty percent? Existing animal studies show that 
physical rehabilitation in the form of voluntary wheel running after VML injury and subsequent 
minced muscle transplant can improve maximal isometric torque, without causing significant 
damage to healing muscle (Corona, Garg et al. 2013). These results suggest that the application 
of force to the repair site during healing can contribute to muscle regeneration. This is supported 
by in-vitro findings that have shown force and substrate strain enhances muscle progenitor cell 
myogenesis (Egusa, Kobayashi et al. 2013, Heher, Maleiner et al. 2015).  Motivated by a desire 
to closely replicate previously reported MM treatment strategies, DSM implants were not sutured 
to the surrounding TA muscle tissue during implantation. In the future we plan to incorporate 
surgical attachment into the repair strategy, as it will enable the transfer of contractile force 
through the repair site during healing and regeneration. In addition to physical stimuli, the 
delivery of soluble stimuli in the form of growth factors has been found to enhance functional 
recovery after muscle injury. Specifically, fibroblast growth factor (bFGF), insulin growth factor 
(IGF), and nerve growth factor (NGF) have been shown to aid in muscle regeneration (Baoge, 
Van Den Steen et al. 2012). If necessary these key molecules could be injected into the repair 
site at the time of surgery to deliver short-term effects, or physically linked to DSM scaffolds to 
potentially prolong their myogenic activity (Ramazanoglu, Lutz et al. 2013).  
The Fischer 344 rats used in this study had not reached skeletal maturity and continued to 
gain weight throughout the recovery period. As a result, the findings reported in this study might 
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more accurately model the response of young adults to VML repair with DSM and MM 
implants. Surgical muscle removal resulting from soft tissue sarcoma resection is another 
anticipated target for VML repair strategies like that described in this study (Fischer, Soimaru et 
al. 2015).  This group of patients is typically older, and to date the regenerative response of MM 
in an aged model has not been investigated. Age related changes in muscle biology might be a 
limiting factor for MM usage in older patients.  It is well established that muscle resident satellite 
cells account for the majority of skeletal muscle’s regenerative capacity (Conboy and Rando 
2005).  However, aging leads to an overall decrease in myogenic capacity mostly in part due to 
reduced satellite cell activity (Snow 1977, Conboy and Rando 2005, Brack and Rando 2007). In 
future studies it would be useful to understand whether the regenerative benefits of MM 
autografts are maintained when harvested from aged muscle. Yet, while the use of MM 
autografts may not be suitable for all VML repair scenarios, the findings reported herein add to 
the growing body of evidence supporting its potential as a VML treatment strategy that warrants 
continued investigation. 
 
 
 
E. Conclusions 
 
The key findings of this study suggest that: 
1. The addition of MM to DSM significantly increased peak TA tetanic contractile force 
when compared to unrepaired VML controls. 
2. DSM+MM repair significantly increased TA muscle mass, restoring approximately half 
of the muscle mass lost to VML injury.  
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3. Histological analysis revealed a reduced fibrotic response at the repair site in response to 
DSM+MM repairs, when compared to either unrepaired VML or isolated DSM repair 
strategies. 
4. MyoD, ECM (Col I and Col III), and ECM regulatory (TGFB1, CTGF, and TIMP-1) 
gene expression levels were significantly increased over all other treatment groups in 
response to DSM+MM repair. 
5.  Analysis of gene expression ratios may provide a useful indicator of VML treatment 
efficacy and restoration of normal muscle homeostasis. 
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Figure Legend 
 
Figure 1: DSM scaffolds were infusion decellularized using a custom-built infusion bioreactor. 
During decellularization, SDS solution was delivered via a hypodermic needle (A) which was 
positioned into the wide mid-belly region of the TA muscle (B). SDS solution was infused via a 
syringe pump (5 ml/hr for 12 hours) through each muscle and outflowed to waste collection. The 
bioreactor was designed to accommodate four side-by-side decellularization units each capable of 
accommodating a single muscle tissue sample (C). Representative whole TA muscle appearance 
prior to and following infusion decellularization treatment (D & E), illustrates the dramatic color 
change (red to white) following removal of intracellular myoglobin. Infusion prepared DSM 
scaffolds, when viewed in thin section (scale bar = 100um) with H&E staining, retained the highly 
aligned architecture of native muscle ECM (F).  (arrow = direction of contraction) 
 
Figure 2: To create the VML injury model, the mid-belly region of the TA muscle in a Fischer 
344 rat was visualized through a 1-2cm incision (A) and approximately 20% of the TA muscle 
(average defect weight = 94±6mg) was excised using an 8mm biopsy punch inserted to a depth of 
3mm (B-D). During isolated DSM repair a single scaffold was cut to size and implanted into the 
TA defect (E). To prepare each MM autograft, 25% of the previously removed defect plug was 
minced with a scalpel and scissors and then used to coat the surface of a single DSM scaffold (F). 
The combined DSM scaffold and MM paste construct was implanted into the TA defect (G). The 
deep fascia and skin (H). were closed separately using absorbable sutures.  
 
Figure 3: Twelve-weeks after treatment, TA peak contractile force was assessed for both 
unrepaired and DSM repaired groups (n=8/group). Representative tetanic force responses for 
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normal, unrepaired VML, DSM, and DSM+MM repaired TA muscles (A). Peak tetanic force was 
normalized to animal weight (N/kg) and computed as a percentage of the untreated contralateral 
limb for each animal tested (B).  Box and whisker plot values shown are the median, 1st and 3rd 
quartile, as well as maximum and minimum. The increase in peak contractile force in response to 
DSM+MM implantation was statically significant when compared to both un-repaired VML and 
isolated DSM repaired samples. (n=7-8 / sample group). # distinguishes significant difference from 
VML group. p<0.05; ANOVA with post hoc Tukey’s test. 
 
Figure 4: Gross morphology of normal, unrepaired VML, DSM, and DSM+MM repaired whole 
TA muscles harvested 12 weeks post treatment (A). TA weight, calculated as the percent normal 
contralateral muscle, was significantly increased in response to repair with combined DSM+MM 
implants (B). The EDL muscle mass was similarly increased in response to treatment, suggesting 
compensatory hypertrophy.  Box and whisker plot values shown are the median, 1st and 3rd quartile, 
as well as maximum and minimum. (n=8/sample); # distinguishes significant difference from 
VML group, p<0.05; ANOVA with post hoc Tukey’s test. 
 
Figure 5:  Representative normal (A, E, I), unrepaired VML (B, F, J), DSM (C, G, K) and 
DSM+MM (D, H, L) repaired histological sections (panel E inset indicates approximate section 
location). Sections were stained with either Masson’s Trichrome or immunostained for the 
presence of MHC (red) and collagen type I (green). The defect/repair site (*) for unrepaired VML 
and isolated DSM repaired samples showed evidence of a thick, collagen enriched, connective 
tissue repair layer. DSM+MM repair site tissue showed markedly less connective tissue formation 
then VML or DSM groups. Dotted line highlights the boundary between collagen dense repair 
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tissue and MHC positive muscle tissue . Scale bar = 250um unless noted  Arrow indicates anterior 
direction. 
 
Figure 6: Representative normal (A, E), unrepaired VML (B, F), DSM (C, G) and DSM+MM (D, 
H) tissue sections. Repair site tissue was immunoreactive to antibodies directed against collagen I 
and III (A-D) as well as laminin and fibronectin (E-F). Scale bar = 100um. Arrow indicates anterior 
direction. 
 
Figure 7: Representative DSM (A) and DSM+MM repaired (B) tissue sections immunostained 
for the presence of collagen type I. The sectional area immunoreactive to collagen type I was 
calculated using sections prepared from tissue regions located at least 3mm away from the anterior 
surface of the muscle. Tissue samples collected from DSM+MM repair samples exhibited a 
significantly lower immunoreactivity to collagen type I when compared to isolated DSM repair 
samples. Scale bar = 100um; n=3/sample group; * distinguishes significant difference from the 
DSM treatment group; p<0.05 ANOVA with Tukey’s 
 
Figure 8. RT-PCR results (fold change compared to normal muscle) for the ECM structural 
proteins Collagen I and III, the ECM regulatory cytokines TGFB1, MMP2, and TIMP-1, and the 
myogenic marker MyoD  Values shown are mean+sem; n=4/sample group;. # distinguishes 
significant difference from both VML and DSM groups; p<0.05 ANOVA with Tukey’s test. 
 
Figure 9: Collagen I to MyoD gene expression ratio versus percent normal contractile force (A) 
for VML, DSM, DSM+MM, and normal TA sample groups. The average expression ratios 
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calculated for VML and DSM samples clustered near an elevated value of 30, while the DSM+MM 
repair sample ratio was better aligned with normal TA muscle. Average expression ratios (B) for 
each of the ECM structural and ECM regulatory genes to MyoD. Expression ratio values shown 
are mean+sem; n=4/sample group.  
 
Supplemental Figure 1: To record peak tetanic contractile force, the hind foot of an anesthetized 
rat was secured to a foot plate with the knee was immobilized at 90° (A). A tenotomy was 
performed on the distal tendons of the EDL and EHL (B & C) to isolate the contribution of TA 
muscle to force production. Needle electrodes were used to stimulate the peroneal nerve (D). 
During stimulation, ankle dorsiflexion force in Newtons versus time was recorded. 
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Abstract: 
Minor trauma, such as contusions and small lacerations, to a skeletal muscle has no lasting effect 
on the force production or morphological structure of the tissue due to the self-repair capabilities 
of skeletal muscle. When trauma is severe and results in a decrease of bulk tissue, the 
characteristic repair mechanisms are overwhelmed resulting in permanent fibrosis and reduction 
in contractile force production. Tissue engineering has yielded several cell and scaffold based 
therapies, and many scaffolds or tissue constructs used in VML repair mimic the parallel 
alignment of myofibers and underlying ECM in skeletal muscle tissue. While the alignment of 
the biomaterial or engineered muscle is addressed in many studies, the relative alignment 
between the tissue engineering construct and the myofibers of the damaged muscle has not been 
thoroughly investigated. This goal of this study was to provide evidence towards the hypothesis 
that the relative alignment of an autograft used to repair VML in an animal model will affect the 
regenerative response of the damaged skeletal muscle tissue. A rat VML model was used with 3 
treatment groups: aligned, 45° unaligned, and 90° unaligned studied at 2 time points: 2 weeks 
(n=6/group) and 12 weeks (n=9) of recovery. We observed significant upregulation of MyoD 
(2.5 fold increase) and Pax7 (1.7 fold increase) expression at 2 weeks post-implantation in VML 
defected muscles repaired with aligned autografts, which provides evidence that congruent 
alignment of a scaffold within a defect contributes to the myogenic response of the repaired 
tissue. After 12 weeks, aligned autografts had greater functional recovery (74.8±10.5%) when 
compared to 45° and 90° unaligned autografts (63.7±10.2% and 60±11.0%, respectively). The 
importance of relative alignment has been demonstrated with this study but the underlying 
mechanisms require further exploration. 
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A. Introduction 
 
 
Volumetric muscle loss (VML) is a skeletal muscle injury in which more than 20% of a 
muscles volume is lost to traumatic injury.(Grogan et al., 2011)Innate mechanisms to repair 
skeletal muscle are overwhelmed and patients are left with permanent fibrosis and functional 
deficiencies. The current standard of care for patients presenting with a VML injury is the use of 
muscle flap autografts. However, there are currently multiple therapeutic interventions being 
developed and tested in animal models, as well as two small clinical studies. Some of the more 
successful strategies include the use of ECM scaffolds. The source of the ECM varies from 
decellularized skeletal muscle (DSM) to porcine small intestine submucosa (SIS). There are 
several differences between the two scaffolds including: pore size, pore alignment, and 
embedded growth factors. Skeletal muscle is a highly aligned tissue with a hierarchical 
arrangement of ECM, and after decellularization the resulting scaffold is anisotropic.(Meyer & 
Lieber, 2011; Wilson et al., 2016) The architecture and mechanical properties of the ECM are 
important not only to provide structure to myofibers, but to transmit mechanical stimuli to the 
myofibers.(Kjaer, 2004) Perhaps more importantly from the standpoint of muscle regeneration, 
mechanical stimuli are imperative for the differentiation of satellite cells and the fusion of 
myoblasts.(Grossi et al., 2007; Tidball et al., 1998) 
Skeletal muscle tissue is highly aligned and the force production of a muscle is heavily 
influenced by the muscles architecture. Muscle architecture, the arrangement of muscle fibers in 
relation to the axis of force generation, is constrained by the length of the muscle, the length of 
myofibers, the pennation angle, and the physiological cross sectional area (PCSA).(Lieber & 
Friden, 2000) Even in pennate muscles, adjacent myofibers have parallel alignment and the 
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surrounding ECM is highly uniform in direction. When designing bioreactors for tissue 
engineered skeletal muscle, researchers are deliberate in developing alignment within their 
constructs.(Aubin et al., 2010; Aviss et al., 2010; Huang et al., 2010b; Vandenburgh & Karlisch, 
1989) Parallel alignment of myofibers has been shown to be important for developing 
phenotypically normal muscle tissue under in vitro conditions.(Aubin et al., 2010; Lam et al., 
2009; Vandenburgh & Karlisch, 1989; Wang et al., 2015) Researchers obtain parallel alignment 
through micropatterning(Cimetta et al., 2009; Flaibani et al., 2009; Huang et al., 2010a; Shimizu 
et al., 2009), aligned deposition of fibers(Aviss et al., 2010; Choi et al., 2008b; Wang et al., 
2015), or by selecting a scaffold that has native parallel alignment. Myofiber alignment 
indicative of a mature muscle phenotype has also been induced in vitro using bioreactors that 
deliver mechanical or electrical stimulation to cells and/or tissue constructs.(Ahadian et al., 
2013; Boonen et al., 2010a; Donnelly et al., 2010; Flaibani et al., 2009; Grossi et al., 2007; 
Langelaan et al., 2011; Powell et al., 2002; Vandenburgh & Karlisch, 1989)  
It has been suggested that parallel alignment is not only necessary for efficient contractile 
force production, but for the arrangement of blood vessels and nerves as well as the migration of 
macrophages, fibroblasts, and muscle progenitor cells during muscle repair. In response to 
sarcolemma damage, satellite cells activate and migrate to the site of tissue insult. Satellite cells 
are capable of migrating across the ECM to adjacent myofibers, but are more likely to travel 
down the length of a myofiber.(Siegel, Atchison, Fisher, Davis, & Cornelison, 2009b) Migration 
of satellite cells is dependent on the release of matrix metalloproteases (MMPs) to degrade the 
basal lamina to allow for efficient chemotaxis to the site of injury.(Kaar et al., 2008) The action 
of MMPs is attenuated by tissue inhibitors of metalloproteases (TIMPs) allowing for increased 
136 
 
cell migration, while limiting the degradation of the supportive ECM.(Karalaki et al., 2009; 
Nishimura et al., 2008) 
The effects of alignment and misalignment on the regenerative response of skeletal 
muscle, especially in cases of VML, are not understood and have not been explored. The 
alignment of a biomaterial when selecting a therapeutic intervention for VML injuries is a 
parameter that many researchers acknowledge.(Merritt et al., 2010; Perniconi et al., 2011b; 
Wang, Johnson, Chang, & Zhang, 2013; Wolf et al., 2012) In another study, researchers used 
autografts to repair VML in an animal model and attributed variance within treatment groups to 
misalignment of the myofibers of the autograft with the myofibers of the VML defected 
tissue.(M. T. A. Li, Willett, Uhrig, Guldberg, & Warren, 2014a) As the field of skeletal muscle 
tissue engineering progresses towards effective treatment options for VML, the effect of relative 
alignment must be understood. 
This goal of this study is to provide evidence towards the hypothesis that the relative 
alignment of an autograft used to repair VML in an animal model will affect the regenerative 
response of the damaged skeletal muscle tissue. More specifically, aligned autografts will have 
greater functional recovery and myogenic activity and decreased fibrosis when compared to 
unaligned autografts. A rat model for VML will be used to assess the effect relative autograft 
alignment has on VML repair.(Wu, Corona, Chen, & Walters, 2012b) Functional recovery will 
be assessed through in vivo electrophysiological testing and repaired muscle mass which will be 
compared to contralateral unaffected limbs. Evidence of myogenesis and fibrosis will be 
ascertained using RT-PCR for quantitative measures of relative gene expression and histological 
analysis will be used for qualitative assessment of the regenerative response of the defected 
muscle. The two time points selected for this study will allow us to explore the initial fibrotic and 
137 
 
myogenic response to alignment or misalignment of an autograft and the long-term recovery 
outcomes for VML defected muscles repaired with aligned or unaligned autografts. 
 
 
B. Methods 
 
Animal Implantation 
 The implantation of 9 animals per group at 12 weeks was determined to be sufficient to 
detect a 15% increase in contractile force between treatment and control animals using a power 
analysis. This level of detection was designed to detect physiologically relevant and functionally 
meaningful increases is muscle contractile force. Pilot testing mean and standard deviation 
contractile force values (1.7±0.3 N/kg and 1.4±0.3 N/kg) collected from repaired and unrepaired 
VML-injured TA samples, respectively, were used for the 2 sample equivalence test.  
Fischer 344 rats (Harlan, Indianapolis, IN), weighing approximately 300-325g were used 
as the animal model for all implantation studies. Surgical procedures and DSM implant 
preparation methods were performed in accordance with protocols approved by the University of 
Arkansas IACUC (protocol #14044) and guided by published methods (Wu, Corona et al. 2012, 
Kasukonis, Kim et al. 2016).  Anesthesia was induced using isoflurane (1-3%) in oxygen. The 
implant site was surgically exposed through a 1-2 cm incision running parallel to the tibia. The 
TA was identified and a sterile surgical marker was used to draw a thin line indicating the 
dominant alignment of the myofibers. A partial thickness VML defect (8 mm diameter x 3 mm 
deep) was created using a sterile biopsy punch (Figure 2). The muscle tissue removed from the 
defect site was weighed (Average defect weight = 93.4 mg). Muscle defect mass values (20% of 
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TA mass) were based on pilot study TA muscle mass measurements (average TA mass = 470±17 
mg). Animals were randomly assigned to one of three treatment groups at  
Group 1: VML repaired with an aligned autograft 
Group 2: VML repaired with a 45° unaligned autograft 
Group 3: VML repaired with a 90° unaligned autograft 
Muscle defect plugs were immediately implanted in the defect site and sutured in place 
with four interrupted stiches with 6-0 polypropylene sutures (Redilene, MYCO Medical, Cary, 
NC). The contralateral limb was left untreated to serve as an internal comparative control. The 
deeper fascia and surface skin layers were separately closed using an interrupted stich with a 5-0 
absorbable suture (Vicryl, Ethicon, Summerville, MA). A single surgeon (BK) performed all 
implantation procedures including the preparation of MM autografts. Postoperative analgesia 
consisted of 0.1mg/kg buprenorphine administered subcutaneously via injection twice daily for 
two days. Animals also had access to the anti-inflammatory medication (Carprofen) via a single 
dietary gel cup (Medigel CPF, ClearH2O, Westbrook, ME) added to each cage following 
surgery. Animal consumption of the gel was voluntary and any uneaten gel was removed from 
the cage at 1-week post surgery. Following surgery, animals were housed in standard-sized rat 
cages with unrestricted movement. The animals were allowed to bear weight on the operative 
extremity as tolerated. All animals were housed for a 2 or 12 week recovery period. 
 
Contractile Force Measurement 
 At the completion of the assigned 2 or 12 week recovery period, the peak tetanic 
contractile force was measured in situ as described in Corona et al (Corona, Garg et al. 2013). 
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Animals were anesthetized and the lower limb was stabilized at 90° of knee flexion (tibia parallel 
to the benchtop) using a custom made alignment jig (Supplemental Figure 1). The ankle was 
flexed to 90° and the foot was secured (surgical tape) to the lever arm of a dual-mode muscle 
lever systems (Aurora Scientific, Ontario, Canada,). To isolate the contribution of the TA during 
force measurement, distal tenotomies were performed on the extensor digitorum longus (EDL) 
and extensor halluces longus (EHL). TA peak isometric tetanic force was measured by 
stimulating the peroneal nerve with the aid of a physiological stimulator (Grass; S88). Optimal 
voltage (2 – 5 V) was determined using a series of tetanic contractions (150Hz, 0.1 ms pulse 
width, 400 ms train). Average peak tetanic force for each animal was calculated from an average 
of 5 contractions. All contractions were separated by one minute of rest. Raw peak tetanic 
contractile force (N) was recorded from both the treated and contralateral control limb of each 
animal and normalized to animal weight (N/kg). The weight normalized force data (N/kg) is 
reported in the results section. At the conclusion of electrophysiological testing and hindlimb 
muscle harvest, all animals were euthanized through a two-part procedure with 4% isoflurane to 
induce anesthesia followed by immediate carbon dioxide inhalation in accordance with 
guidelines provided by the 2013 AVMA Panel on Euthanasia of Animals.  
 
Tissue Histology 
 Autograft repaired TA muscles along with contralateral untreated TA muscles were 
harvested and trimmed to remove the periosteum and tendon. EDL muscles were also collected 
and weighed for comparison between treated and contralateral control limbs. Muscles were 
rinsed in sterile PBS, dabbed dry, and then weighed. Muscles were then immediately flash frozen 
in liquid nitrogen cooled isopentane. 12 week frozen TA tissue samples (n=4/experimental 
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group) were sectioned (10μm) transversely through the mid-portion of the defect site with the aid 
of a cryostat. Sections were mounted onto microscopic slides and immuno-stained for the 
presence of collagen type III (αColIII, 1:500, Abcam) followed by incubation in the appropriate 
fluorescently labeled secondary antibody (Alexfluor, 1:500, Life Technologies). These sections 
were analyzed using ImageJ to determine the average myofiber area. Other 12 week transverse 
sections were stained with H&E (VWR) using standard protocols. Tissue sections from 2 week 
time points were obtained by slicing the frontal plane of whole muscle. These 10μm sections 
were stained using a commercial Masson’s Trichrome kit following manufacturers guidelines 
(Sigma). All sections were mounted onto microscope slides and digitally imaged. Treated 
sections were evaluated for myofiber formation and organization as well as the formation and 
extent of repair tissue formation for comparison to untreated contralateral muscle tissue sections.  
Myogenesis and ECM Gene Expression  
Real-time PCR was performed using the protocol described in Washington et al. 
(Washington, Brown et al. 2013) Tissue samples (approximately 30mg) collected from the 
defect/repair site (n=4/sample group/time point) were homogenized with Trizol (Ambion, 
Carlsbad, CA), chloroform (Sigma Aldrich, St. Louis, MO), and treated with DNase (Invitrogen, 
Carlsbad, CA). RNA was extracted using the RNeasy kit (Invitrogen, Carlsbad, CA). RNA 
concentration and purity was determined by UV spectrophotometry. RNA with a 260-to-280-nm 
ratio ≥ 1.8 was used for subsequent analysis. cDNA was reverse transcribed from 1 µg of total 
RNA using the Superscript Vilo cDNA synthesis kit (Life Technologies, Carlsbad, CA, 
USA). cDNA was amplified in a 25 µL reaction containing appropriate primer pairs and TaqMan 
Universal Mastermix (Applied Biosystems, Grand Island, NY). Commercially available 
TAQMAN primers (Invitrogen, Carlsbad, CA) for MyoD, Pax7, Timp-1, Collagen I, Collagen 
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III, TGF-β1, MMP2, and 18s ribosomal housekeeping were used to quantify the expression of 
desired matrix and matrix regulatory genes. Samples were incubated at 95°C for 4 minutes, 
followed by 40 cycles of denaturation, annealing, and elongation at 95°C, 55°C, and 72°C, 
respectively. TaqMan fluorescence was measured at the end of the extension step each 
cycle.  Experimental group samples were normalized to 18s and then referenced to the 
contralateral normal limb. Gene expression levels are reported as fold change using the 2-(Δ ΔCt) 
method. 
 
Data Analysis 
 All data are represented by the mean and standard error unless noted. Data were tested for 
normality using the Shapiro-Wilk Test. Each time point was considered separately and no 
comparisons were made between treatment groups of different recovery times. Comparisons 
between treatment groups (Aligned, 45° Unaligned, and 90° Unaligned) for each of the outcome 
measures (peak force, muscle mass, and gene expression) were evaluated with a one-way 
ANOVA using a commercial statistical software package (JMP). Post hoc comparisons were 
made using Tukey’s HSD. A standard 0.05 level of significance was used for all statistical tests. 
 
 
C. Results 
 
Defect Creation and Autograft Implantaion 
The defect creation and autograft implantation took approximately 40 minutes to 
complete.(Figure 2) All autograft treatment groups tolerated the implantation surgery well. All 
animals gained weight throughout the first two weeks at a rate of 7.1±4.0grams/week. Animals 
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gained an average of 7.2±1.1 grams/week over the long-term recovery period (12 weeks). There 
were no signs of post-surgical infection. At one week post-implantation, all animals were fully 
ambulatory with no noticeable gait differences between groups. Carprofen dietary gel cups were 
typically consumed within the first 3 days of surgery (effective dosage (5/mg/kg/day). All 
animals reached the assigned 2-week or 12-week study end point without complications.  
 
Contractile Force Measurement 
After the 2-week or 12-week recovery period, bilateral measurements of the isometric TA 
muscle tetanic contractile force were obtained. Tetanic contraction plots for all muscles were 
characterized by a sharp rise in force, followed by a plateau at the peak force, and then a return 
to a no force resting state (Figure 3). The average peak tetanic force produced by normal 
contralateral TA muscles was 2.5±0.1 N/kg at 2 weeks post-implantation when normalized to 
animal mass and 2.5±0.2 N/kg after 12 weeks. Following VML injury with aligned autograft 
repair, the average peak tetanic force dropped to 1.2±0.2 N/kg after two weeks, which is 
equivalent to 48±8% of normal contralateral TA muscles values, a statistically significant 
reduction (p<0.05). However, after 12 weeks of recovery, muscles repaired with aligned 
autografts produced 1.8±0.3 N/kg of force, representing 75±11% of the peak tetanic contractile 
force of normal muscle. Following repair with 45° unaligned autografts, TA muscles produced 
an average contractile force of 1.3±0.3 N/kg after two weeks, which represents 51±11% of the 
peak force of the control muscle group. After 12 weeks, the muscles repaired with 45° unaligned 
autografts had 1.6±0.2 N/kg of force when normalized to body mass, representing 64±10% of 
force of normal muscle at the same time point. In response to repair with 90° unaligned 
autografts, the average peak tetanic force increased to only 1.5±0.3 N/kg after 12 weeks of 
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recovery compared to 1.3±0.3 N/kg of force at 2 weeks, which represents 61% and 53% of the 
force production of body mass normalized control muscle peak contractile force at the same time 
points.  
Muscles harvested at 2 weeks of recovery showed remarkable morphological differences 
between all treatment groups and all treatment groups compared to the contralateral control 
muscles.(Figure 4) There was minimal fibrosis around the polypropylene stitches and no 
evidence of ineffective approximation of defect-autograft margins. Muscles repaired with a 90° 
unaligned autograft displayed the most deformity at the defect site. A fibrotic strip of tissue 
which occupied the entire defect vertically (8mm) and about 2-3mm in the horizontal direction 
was observed in all of the 90° unaligned autograft treatment group at 2 weeks post-implantation 
(Figure 4). The muscles repaired with the 45° unaligned autografts did not display any distinctive 
features, but the defect site appeared to be generally more disorganized and fibrotic than normal 
contralateral muscle. The defect site of muscles receiving the aligned autograft were closest to 
contralateral muscle at 2 weeks post-implantation and the margins of the autograft were just 
visible with the naked eye. For all muscles harvested following 12 weeks of recovery, there was 
no evidence of implant site infection or gross deformity at the treatment site. There was no 
obvious patterns of fibrosis in any of the treatment groups, although there appeared to be 
progressively more atrophy as degree of misalignment increased. The muscles repaired with 
aligned autografts appeared to have less atrophy at the treatment site and less disorganization 
overall when compared to the unaligned autograft repaired muscles. Although the aligned 
treatment group displayed evidence of repair at the defect site, treated muscle was remarkably 
similar to contralateral normal muscle. At 12 weeks post-implantation, 45° and 90° unaligned 
treatment groups were undistinguishable from each other and general appearance at the defect 
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site was characterized by degenerated tissue and disorder of myofibers.  Aligned treatment 
animals had a body weight normalized average TA mass of 1.37±0.1 g/kg at 2 weeks and 
1.39±0.1 g/kg at 12 weeks, which is 82±5% and 89±7% of the contralateral normal TA mass at 
the respective time points. Two weeks after defect creation and repair, TA muscle defects 
repaired with 45° unaligned autografts had an average normalized mass of 1.37±0.1g/kg, which 
is 82±5% of contralateral normal muscle mass and after 12 weeks the muscles had an average 
mass of 1.37±0.1g/kg, which is 88±7% of contralateral normal muscle mass when normalized to 
body weight. The group of TA muscles repaired with 90° unaligned autografts had an average 
mass of 1.30±0.2g/kg after 2 weeks and 1.35±0.1g/kg after 12 weeks, which is equivalent to 
78±9% and 86±8% of contralateral normal values at the respective time points. All treatment 
group muscle masses were significantly decreased when compared to contralateral control 
groups of their respective time points (p<0.05), but were not significantly different from other 
treatment groups of the same recovery length.  
Six key genes associated with ECM structural proteins (collagen I and III), ECM 
regulatory cytokines (TGF-β1, MMP2, and TIMP-1) and 2 genes related to myogenesis (MyoD 
& Pax7) were examined with the aid of rt-PCR. (Figure 5). The muscles recovered at two weeks 
post-implantation had an across the board upregulation of ECM associated genes for all 
treatment groups. For TGF-β expression, the fold change was 4.4±0.8, 2.6±0.4, and 3.3±1.4 for 
aligned, unaligned 45°, and unaligned 90°, respectively. Collagen I expression in the autograft 
repaired muscles had the greatest fold change compared to normal muscle expression with 
aligned having 11.6±4.2 fold change, unaligned 45° with a 8.1±1.7 fold change, and unaligned 
90° had a 12.0±7.4 fold change. Collagen III expression in the autograft repaired muscles had 
significant increases compared to normal muscle expression with aligned having 9.1±2.7 fold 
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change, unaligned 45° with a 7.5±1.8 fold change, and unaligned 90° had a 7.6±4.1 fold change. 
MMP2 had a significant increase in expression in all treatment groups compared to the uninjured 
control muscle expression levels with fold changes of 7.3±1.4, 6.6±1.4, and 6.5±2.9 for aligned, 
unaligned 45°, and unaligned 90°, respectively. Timp-1, an MMP inhibitor, also had significantly 
increased expression in all treatment groups compared to uninjured muscle expression with 
aligned having 10.2±3.5 fold change, unaligned 45° with a 7.9±2.1 fold change, and unaligned 
90° had a 8.1±4.6 fold change. Alternatively, the aligned autograft repaired muscle group 
produced a statistically significant increase (p<0.05) in the expression of MyoD with a fold 
change of 2.5±0. 7 and of Pax7 with a fold change of 1.7±0.1 when compared to normal TA 
muscle samples. The unaligned repaired muscle expression did not have a significant difference 
with the uninjured TA expression of myogenic genes. After 12 weeks of recovery, the autograft 
repaired muscle did not have any significant difference in ECM or myogenic gene expression 
when compared to the relative expression of uninjured TA muscle.  
At 2 weeks post-implantation, Masson’s trichrome staining revealed signs of increased 
collagen deposition (blue staining) at the defect site in all treatment groups. The locations and 
amount of collagen varied between treatment groups. (Figure 6) Muscles repaired with aligned 
autografts had increased collagen at the margins of the defect but evidence of myofibers at the 
most interior parts of the autograft. Alignment of the myofibers appeared to be in-line with 
surrounding myofibers of the TA. Unaligned autograft repair led to an increase in collagen 
deposition when compared to the aligned repair. Unaligned 90° repaired muscles were the most 
fibrotic with defect sites characterized by disorganization and lack of myofibers. Collagen 
deposition was not limited to the defect site but was more prevalent through most of the muscle. 
Unaligned 45° repair had an intermediate amount of fibrosis at the defect site and there was 
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evidence of myofibers at the defect with alignment incongruent with the surrounding tissue 
orientation. As observed in the unaligned 90° repaired muscles, the unaligned 45° repair had 
evidence of increased collagen deposition beyond the margins of the defect. The defect sites all 
retained a small number of myofibers in the original implanted alignment.  
At 12 weeks post surgery, the defect sites were detectable in histological sections 
prepared from all treatment groups. There was evidence of fibrotic tissue at the surface of the 
defect site for all treatment groups with little deviation between groups. (Figure 7) The average 
fiber diameter was not significantly different between groups, suggesting that any functional 
improvement observed in muscles repaired with aligned autografts was not due to hypertrophy. 
(Figure 7)  
 
 
D. Discussion 
 
The results from this study indicate that the alignment of an autograft has a significant 
effect on the regenerative response of the surviving muscle. By varying only the alignment of 
fibers relative to the damaged muscle, we ensured that only relative fiber alignment could 
generate differences between the treatment groups. After the creation of the VML injury and 
weighing the autograft, the autograft was immediately placed back into the defect site while the 
margins of the defected muscle were still bleeding. The autograft was aligned according to the 
relative angle between the TA myofibers and the myofibers of the autograft as indicated by the 
line drawn prior to defect creation. The alignment of the autografts was straightforward for the 
aligned and 90° treatment groups, the 45° treatment group was an intermediate treatment 
between the aligned and 90° groups. Although the angle was not measured, the intermediate 
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nature of the 45° treatment group would allow us to determine if the repair response was 
proportional to the relative alignment or, as was seen in contractile force measurements, 
histological analysis, and gene expression data, muscle only regenerated in response to aligned 
autografts and responded to any degree of misalignment with increased fibrosis and atrophy 
resulting in a functional deficit.  
Polypropylene sutures served as anchors to maintain the relative alignment of the 
autografts and to allow for mechanical force transduction through the autograft and to the distal 
myofibers which were severed upon creation of the VML injury. Four sutures were determined 
to be the minimum required to preserve the prescribed alignment or misalignment while limiting 
the incidence of foreign body response and encapsulation by the host immune system, which is a 
concern for non-resorbable biomaterials.(Anderson et al., 2008) Polypropylene sutures were 
selected as they would provide consistent and effective mechanotransduction through the 
autograft. Mechanotransduction, the conversion of mechanical stimuli through tissue into 
biochemical signals by cells, is known to improve myogenesis in vitro and in vivo.(Boonen et al., 
2010b; Martineau & Gardiner, 2001) Mechanotransduction may contribute to the response of the 
host skeletal and immune systems to therapeutic interventions with varying mechanical 
properties. Scaffolds and tissue constructs with mechanical properties incongruent to native 
skeletal muscle could deliver mechanical stimuli outside the thresholds necessary for 
myogenesis.(Courtney, Sacks, Stankus, Guan, & Wagner, 2006; Takaza, Moerman, Gindre, 
Lyons, & Simms, 2013)  
The fibrotic strip observed in the gross morphological analysis of the 90° unaligned 
treatment group after 2 weeks of recovery provides evidence of ineffective skeletal muscle 
repair. Studying the formation and subsequent disappearance of this feature could facilitate an 
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investigation into the mechanisms by which relative misalignment affects the regenerative 
response of VML injured muscle.  Although the fibrotic strip was not clearly visible with 
Masson’s trichrome stain, other staining protocols may yield better results. The increased 
collagen deposition outside the margins of the defect may obfuscate a collagen-rich feature as 
was observed with the Masson’s trichrome stained sections.  
The significant upregulation of myogenic genes during the first 2 weeks of recovery and 
the near significant improvement in peak tetanic contractile force after 12 weeks, provides 
evidence that the relative alignment between an autograft and myofibers of a VML injured 
muscle is significant to the determination of a fibrotic or myogenic response by the damaged 
skeletal muscle. This cannot be extrapolated to conclude that a significant difference exists 
between the regenerative response to anisotropic scaffolds with mechanical properties similar to 
skeletal muscle, such as DSM,(Wilson et al., 2016) and to isotropic scaffolds, such as SIS or 
UBM. Evidence published recently suggests that there is no significant differences with respect 
to the regenerative capacity of repair with DSM compared to UBM, although the study used an 
abdominal wall model which does not have the same design requirements and challenges as 
extremity VML injury models with respect to volumetric repair and desired functional 
outcomes.(Wolf et al., 2012) 
The results of RT-PCR give evidence of a transient remodeling phase which was present 
at 2 weeks as evidenced by the upregulation of ECM related genes in all treatment groups and a 
return to baseline levels of gene expression after 12 weeks of recovery. The significant 
upregulation of MyoD and the upward trend of Pax7 expression in VML defected muscles 
repaired with aligned autografts provides evidence that congruent alignment of a scaffold within 
a defect contributes to the myogenic response of the repaired tissue. There did not appear to be a 
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continuum of responses in gene expression with respect to the relative angle of misalignment. 
The unaligned scaffolds performed similarly to each other with upregulation of ECM related 
genes at the 2 week time point and a return to baseline levels after 12 weeks. The disorganization 
of the defect site in both unaligned treatment groups was evident at 2 and 12 weeks of recovery 
The mechanisms by which alignment contributes to the regenerative response of host 
muscle after VML cannot be elucidated by the methods of this current study. Further studies at 
intermediate time points could track the facilitation or retardation of blood vessel in growth or 
the infiltration of the autograft by macrophages, muscle progenitor cells, and myofibroblasts. 
The use of GFP+ rats could provide a platform to investigate autograft fate, including cells and 
damaged myofibers, after being implanted into a volumetric defect. An autograft from the 
creation of a VML defect in a GFP+ rat could be implanted into the VML defect of a GFP- rat 
and the reverse could be performed simultaneously. The use of an inbred strain of rat, such as 
Fischer 344 rats, would eliminate the host rejection response and allow for innate regenerative 
responses to predominate over foreign cell immune reactions. There still exists a knowledge gap 
into the mechanisms that cause fibrosis at the defect site, yet allow for significant functional 
recovery. The hypothesis of a functional fibrotic repair deserves further exploration, especially 
exploring the muscle as a whole instead of limiting research simply to the defect site.The use of 
unaligned grafts may help clarify the fibrotic response the VML repair and help guide more 
effective strategies.  
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E. Conclusions 
 
The key findings of this study suggest that: 
1. VML defected TA muscles repaired with aligned autografts had improved peak tetanic 
force production over muscles repaired with unaligned autografts after 12 weeks of 
recovery. 
2. There was no significant difference in TA mass between aligned and unaligned treatment 
groups at short-term or long-term recovery time points  
3. At two weeks post-implantation, only muscles repaired with aligned autografts displayed 
increased expression of myogenic genes (MyoD & Pax7), while all treatment groups had 
increased expression of ECM/fibrotic genes (Col I, Col III, TGF-β, MMP2, and Timp-1) 
4. By 12 weeks post-implantation, muscles had reached base line levels for all gene 
expression and were morphologically similar with respect to fibrosis at the surface of the 
defect site. 
5.  The differences seen histologically at 2 weeks of recovery between aligned and 90° 
unaligned autograft treated muscle warrant further study as to the mechanisms leading to 
a fibrotic vs. myogenic regenerative response. 
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Figure Legend 
 
Figure 1:  Experimental abstract. A VML defect was created in the left TA of Fisher 344 rats. 
The defect was repaired with autografts from one of three treatment groups: Aligned, 45°, or 90°. 
Autografts were secured in place with polypropylene sutures to maintain prescribed alignment. 
Animals were assigned to one or two recovery periods, 2 weeks (n=6/group) or 12 weeks 
(n=9/group). Electrophysiological data was collected for both the repaired TA muscle and the 
contralateral control TA muscle. TA muscles were harvested, weighed, and prepared for RT-
PCR or histological analysis. 
 
Figure 2:  Surgical procedure. A ~1.5cm incision parallel to tibia was made in the left hind limb 
of Fischer 344 rats (A). The skin and fascia was dissected to reveal the TA and a mark was 
drawn onto the TA with a sterile surgical marker to indicate the direction of the myofiber 
alignment (B). An 8mm biopsy punch was used to create a volumetric defect in the TA. A 
PDMS ring was used to ensure a defect depth of 3mm (C). The defect plug was weighed and 
then placed into defect as an autograft at the assigned alignment (90° unaligned pictured) (D). 
The autograft was sutured in place using polypropylene sutures to maintain appropriate 
alignment or misalignment (E). The wound was closed using double layer closure of the fascia 
and skin utilizing absorbable sutures with interrupted stitches (F). 
 
Figure 3:  Electrophysiological data. Contraction of the TA was induced by stimulating the 
peroneal nerve. Force was measured by securing the foot to the foot plate of a force transducer. 
The average percent recovery (A) for the three treatment groups at the two time points along 
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with the body weight normalized (N/kg) mean peak tetanic force produced (B) is shown for the 
three treatment groups and control TA muscles at the two recovery time points. A representative 
force profile for each treatment group is shown (C). n = 6/group at 2 weeks and n = 9/group at 12 
weeks. Values are mean + SD. 
 
Figure 4:  Gross morphology. Representative samples of the autograft repaired muscles are 
shown immediately after being secured into the VML defect (t = 0) and after being harvested at 
either 2 or 12 weeks for each of the three treatment groups: Aligned, 45°, or 90° (A). TA muscles 
were harvested, weighed, and the mass was normalized to body weight (g/kg) for each of the 
treatment groups (B). n = 6/group at 2 weeks and n = 9/group at 12 weeks. Values are mean + 
SD. * indicates significant difference from the body weight normalized control TA at the same 
time point. (p < 0.05 with ANOVA with Tukey’s HSD) 
 
Figure 5:  Gene expression. RT-PCR was used to determine the relative expression of ECM 
related structural proteins and regulatory factors Collagen I and III, TGFβ, MMP2, Timp1 and 
myogenic markers MyoD and Pax7. n = 4/group at 2 weeks and n = 4/group at 12 weeks. Values 
are mean + SE. * indicates significant difference from the relative expression of that gene for the  
control TA at the same time point. (p < 0.05 with ANOVA with Tukey’s HSD) 
 
Figure 6:  Histology. Representative whole muscle sections of autograft repaired TA muscles at 
2 weeks stained with Masson’s trichrome for aligned (A), 45° (B), 90° (C). Representative 
samples stained with Masson’s trichrome showing relative alignment of autograft still present at 
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2 weeks for aligned (D), 45° (E), 90° (F). * indicates myofibers still in their implanted 
alignment. Black scale bar = 1mm. White scale bar = 100µm. 
Figure 7:  Long-term recovery. Representative transverse sections at the surface of the defect 
site of muscle repaired with aligned (A), 45° unaligned (B), and 90° unaligned (C) autografts 
stained with H&E. Representative transverse sections of muscle repaired with aligned (D), 45° 
unaligned (E), and 90° unaligned (F) autografts immunostained for Collagen III. Average 
myofiber area (G). Values are mean + SD. Black scale bar = 100µm. White scale bar = 100µm.  
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Chapter 5 
 
Conclusion 
 
A. Evaluation of Muscle Regeneration 
 
 Skeletal muscle tissue engineering is still a relatively new field within biomedical 
research, although evidence of initial explorations into the plasticity and “repairability” of 
muscle date back more than a century.(Bursac et al., 2015; Thompson, 1971) The fact that 
physicians still have few options when it comes to repairing VML necessitates further 
innovation. The most successful strategies so far have combined scaffold and cell-based 
approaches to deliver a construct that directs innate repair mechanisms towards a myogenic 
response rather than fibrosis.(Aurora et al., 2015; Merritt et al., 2010; Page et al., 2011; Ward et 
al., 2015) Moving forward, researchers should first start with a consensus of what constitutes 
success in a strategy or technique to improve tissue regeneration after muscle trauma.  
Contractile force measurements 
 The first and primary measure of success in skeletal muscle repair must be anchored in 
the contractility of the repaired tissue. Skeletal muscle without contractility ceases to perform its 
role within the human body and eventually develops into fibrotic tissue. Cosmetic appearances 
are certainly important from a clinical perspective and improvements in patient satisfaction after 
a traumatic injury are needed.(Mase et al., 2010) Likewise, other parameters used to evaluate 
skeletal muscle repair and regeneration after traumatic injury, such as histological and 
biomolecular measurements and observations, are very important from a research standpoint as 
they allow investigators to elucidate mechanisms involved in the repair process and serve as 
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snapshot of a certain aspect of regeneration. However, the priority needs to be placed on the 
functional recovery from a traumatic injury that negatively impacts the patient’s freedom and 
quality of life. 
 There are several methods for measuring contractile force in animal models and human 
patients. In animal models there seems to be a consensus around the use of in vivo or in situ peak 
tetanic contractile force as adequate measure of skeletal muscle function.(Corona, Ward, Baker, 
Walters, & Christ, 2013; Grasman, Do, Page, & Pins, 2015; Han et al., 2016; M. T. A. Li, 
Willett, Uhrig, Guldberg, & Warren, 2014b; Merritt et al., 2010; Mintz, Passipieri, Lovell, & 
Christ, 2016; Page et al., 2011; Valentin, Turner, Gilbert, & Badylak, 2010) Peak tetanic 
contractile force is obtained by immobilizing the joint proximal to the defected muscle and 
electrodes are positioned to stimulate the nerve responsible for innervating the muscle of interest. 
The appendage distal to the defected muscle is secured to a force transducer and when the 
muscle is stimulated using parameters known to induce peak contraction, the force produced by 
the muscle is measured. Peak tetanic contractile force is not the only in vivo measure of force 
used, other studies have used twitch force(Han et al., 2016) and others have selected fatigue 
testing.(Corona et al., 2013b; M. T. A. Li et al., 2014b) All protocols produce physiological 
relevant data for evaluating the functional recovery of muscle from a VML injury. 
 
Histology 
 Histological data provides researchers with data to elucidate spatial differences in VML 
animal repair models. Direct measurements of morphological features and physiological 
adaptations to the VML repair microenvironment are possible through thin sectioning of repaired 
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skeletal muscle tissue. Appropriate staining protocols and visualization techniques allow 
researchers to investigate the following broad categories: myogenesis, fibrosis, vascularization, 
and innervation. Protocols for the histological analysis of in vivo myogenesis include 
immunofluorescent stains for transcription factors such as Pax7, MyoD, and Ki67, and for 
sarcomeric features such as embryonic-myosin heavy chain. Another technique for determining 
myogenic activity is to observe sections for centrally located nuclei and other morphological 
features indicative of differentiating muscle progenitor cells. Fibrosis within histological samples 
can be determined through any staining protocol that locates the deposition of collagen and other 
ECM constituents. The presence of collagen can be observed with techniques for brightfield 
microscopy such as Masson’s trichrome or immunohistochemical staining. Immunofluorescence 
can also be used to locate collagen. If care is taken to ensure that thin muscle sections have exact 
exposure times (i.e. batch processing), quantitative data can be obtained from these histological 
techniques. 
  
Biomolecular Response 
Another area of methods for gathering quantitative and qualitative data in the field of 
skeletal muscle tissue engineering and regenerative medicine is to use protocols that provide data 
on the biomolecular response of skeletal muscle tissue. The techniques could broadly include: 
Western blotting, ELISA, biomolecular assays, RT-PCR, and gel electrophoresis. While Western 
blots, gel electrophoresis, and ELISA techniques are not typically found in studies concerned 
with investigating VML repair, RT-PCR is used in many studies to give researchers evidence of 
cellular responses to regenerative therapies. Most published papers in the field generally examine 
genes related to fibrosis (Collagen I & III, TGF-β, MMP1 & 2 & 9, Timp-1, CTGF) and 
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myogenesis (MyoD, myogenin, Myf5, Pax3, Pax7). RT-PCR is an excellent tool to facilitate 
investigations into the mechanisms of repair in skeletal muscle since it provides researchers with 
snapshots of cellular activity at the prescribed timepoint.  
 
Effect of Age 
 Almost all studies investigating skeletal muscle after VML in a rat model have been 
performed on young (< 6 months old) rats. There has only been one study involving VML in an 
aged rat model.(J. T. Kim, Kasukonis, Brown, Washington, & Wolchok, 2016) Regeneration 
after VML was markedly decreased for all aged animals and preliminary results have shown that 
DSM +MM repaired muscles had no significant improvements in contractile force recovery 
compared to VML controls. Studies have suggested the decrease in the regenerative capacity of 
satellite cells in aged muscle is due to age-related changes in the microenvironment of the 
muscle and not necessarily due to age-related changes intrinsic to the cell.(Conboy, Conboy, 
Smythe, & Rando, 2003; Conboy et al., 2005) Further studies should be performed in aged 
animal VML models to validate techniques that have demonstrated success in younger animal 
models. 
 
 
B. Further Characterization 
 
  
A study presented previously in this dissertation used DSM and MM together as a 
construct for skeletal muscle regeneration after VML. Previous studies have shown that a DSM 
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scaffold alone and a MM autograft made up of 25% of the defect volume with enough collagen 
gel to completely fill the defect were not effective treatments for inducing muscle regeneration in 
animal VML models.(Kasukonis et al., 2016; Sicari et al., 2014; Ward et al., 2015) In addition to 
determining the optimal ratio of DSM:MM to repair VML, further work should be done to 
investigate each constituent for more complete characterization and to ensure future clinical 
studies have maximum regenerative potential. 
 
Advantages of DSM 
 Although it has been established that DSM or any other acellular scaffold alone is not 
sufficient to regenerate skeletal muscle after VML, DSM can be a component in an effective 
strategy for repairing VML.(Kasukonis et al., 2016; Merritt et al., 2010) DSM maintains an 
advantage over other acellular ECM scaffolds in that DSM is composed of aligned ECM, 
contains skeletal muscle specific ECM-bound growth factors, and cadaveric skeletal muscle is 
plentiful. With techniques similar to the one outlined previously in this dissertation, production 
of DSM scaffolds for large VML injuries would be possible.(Kasukonis, Kim, Washington, & 
Wolchok, 2016) There are still several studies that should be performed to further characterize 
DSM, not only as a scaffold but as a template for engineered ECM constructs that by using ECM 
harvested from cell cultures, would eliminate the need for donor tissue.(Hurd, Bhatti, Walker, 
Kasukonis, & Wolchok, 2015)  
These future avenues of research include determining if the source of the ECM has any 
effect on the regenerative response of the host tissue. Previous studies have shown that there are 
differences in the starting composition of ECM derived from different muscles, but the challenge 
170 
 
is to discover if those differences correspond to increased or decreased regenerative potential. 
Another question that needs to be answered is, does the degradation of ECM scaffolds before 
they are implanted have any effect on their regenerative potential in the context of VML repair. 
Decellularization protocols have been developed to lessen the degradation of ECM during the 
process of lysing and stripping cells, but does that matter in the VML wound niche?(Gillies et 
al., 2010) During the initial inflammatory response, macrophages will dismantle the donor ECM 
as remodeling begins within the wound site. If the scaffold has been preconditioned with various 
levels of degradation, will the remodeling response follow more myogenic or more fibrotic 
pathways? Conversely, can the ECM scaffold be “functionalized” with growth factors in order to 
affect the regenerative response of the host tissue? Continued exploration along these lines could 
help push scaffold based therapies from 80-85% force recovery to 90-95% recovery. In 
summary, even though in isolation DSM scaffolds will not generate an effective myogenic 
response, further improvements to the scaffold should be investigated. 
  
Advantages of MM 
 The use of MM as a constituent in a repair strategy appears to be the most promising 
method of delivering cells and physiological cues to the site of VML.(Corona et al., 2013b; 
Kasukonis et al., 2016) Autologous MM has an advantage over any allogeneic cell transplant in 
that it does not require immunosuppressant drugs. It has an advantage over any isolated 
autologous stem cell line because it is as close to off-the-shelf as cells can be with current 
technologies. Most surgical suites do not contain the necessary apparatus for cell culture. In 
addition, and more importantly, isolation and proliferation of a stem cell line would require a 
preliminary procedure to harvest cells and several days or weeks to isolate the stem cells and 
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expand them to a therapeutic level. This additional procedure to harvest cells could lead to 
increased chance of infection and patient discomfort. Conversely, harvesting and mincing tissue 
is certainly within the current skillset of surgeons and nurses within an operating room and could 
be a procedure that is performed with concurrent to VML repair.(Ward et al., 2016) MM should 
also be preferred to isolated stem cells or other muscle progenitor cells because it also delivers 
pro-inflammatory and pro-myogenic factors to the defect site at the time of implantation. The 
studies completed by the US Army Institute of Surgical Research team have shown the response 
of surviving tissue to MM autografts is favorable for de novo formation of myofibers in the 
defect area.(Corona et al., 2013b; Ward et al., 2015) Several questions remain regarding the 
characterization of the initial MM but also the spatiotemporal response of the surviving muscle 
and immune system to the MM autograft. Much as the innate regenerative processes of muscle 
can be broken down into timelines of minutes and hours, then days and weeks, the response of 
the initial immune and long-term fibrotic vs. myogenic remodeling that follows implantation 
should be further studied. Evidence presented earlier in this dissertation indicates that even 
though MM appears to induce myogenesis there appears to be long-term upregulation of genes 
associated with fibrosis.(Kasukonis et al., 2016) MM has already shown potential as an autograft 
and further characterization could potentially lead to a reduced donor volume being necessary if 
scaffolds could be preconditioned with growth factors or cytokines after their relative importance 
to muscle regeneration in a VML injury niche is determined. 
 Other studies should explore the effect the location of source muscle has on the 
regenerative capacity of MM. Related studies must be done to determine the most effective 
harvesting technique. One possibility is maximize the amount of donor tissue while minimizing 
donor site morbidity or fibrosis could be to “mesh” biopsy a donor muscle similar to methods 
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used to prepare autologous skin grafts.(Tanner, Vandeput, & Olley, 1964) Instead of taking a 
smaller surface of skin and meshing it to stretch to the desired surface area, donor muscle would 
be left in place and several small volume biopsies could be taken to give the desired quantity.  
This leads to the next avenue of inquiry: What is the smallest biopsy that can be taken 
from a muscle such that it suffers no long-term negative effects? A recent study to investigate the 
regenerative potential of isolated MSC delivered with a fibrin glue inadvertently found that a 
5mm biopsy from the TA of a rat was insufficient to produce an irrecoverable defect.(Pereira et 
al., 2014) When force measurements were obtained 35 days after the creation of a defect, there 
was no significant difference between the peak tetanic force produced by the defected muscle 
and uninjured muscle.(Pereira et al., 2014) Of course further studies should be performed to 
determine if multiple biopsies from a donor muscle will afford researchers enough donor MM 
without any deleterious effects on the donor tissue.  
 
Effects of Alignment 
 Although micropatterning and aligned engineered scaffolds induce myoblast and 
myofiber alignment under in vitro conditions, (Aviss et al., 2010; Choi et al., 2008b; Hinds, 
Bian, Dennis, & Bursac, 2011; Huang et al., 2010b; Lam et al., 2009)  it has been demonstrated 
that mechanical and electrical stimuli also produce aligned myofibers under the same 
conditions.(Boonen et al., 2010b; Donnelly et al., 2010; Langelaan et al., 2011; Pennisi, Olesen, 
de Zee, Rasmussen, & Zachar, 2011; Tatsumi, 2010; Vandenburgh & Karlisch, 1989)   
 One aspect about the effect of fiber alignment on skeletal muscle repair that needs to be 
determined is whether the location of the defect has any bearing on how much alignment matters. 
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Many of the studies that used porcine SIS and other scaffolds with no alignment seem to have 
success repairing abdominal wall defects.(Prevel et al., 1995; Valentin et al., 2010) While this 
could be due to the “functional fibrosis” described by a different group, it could also be due to 
the location of the injury.(Corona et al., 2013a) If abdominal wall injuries and extremity muscle 
injuries respond differently to fiber alignment, more specific strategies could be developed to suit 
each injury niche. 
 
 
C. Future Directions for VML 
 
 Rehabilitation 
When human patients suffer musculoskeletal trauma, the standard of care in almost all 
cases involves physical rehabilitation. However, post-implantation protocols in small animal 
models do not consistently include exercise such as voluntary running wheels. Some studies have 
included physical rehabilitation in both VML model and in stem cell based interventions for 
myopathies such as DMD.(Ambrosio et al., 2009; Bouchentouf, Benabdallah, Mills, & 
Tremblay, 2006; Corona et al., 2013b) Rehabilitation was shown to improve outcomes in the 
cases of stem cell transplants and there were mixed results with the exercise treatment group in 
the VML animal model.  
A different study indirectly highlights the effect rehabilitation can have on muscle that 
suffers traumatic injury. A murine model in which myotoxin-induced direct muscle damage and 
hind limb ischemia were used for skeletal muscle trauma.(Cezar et al., 2016) Cyclic mechanical 
compression was applied through a pressure cuff or a biphasic ferrogel scaffold which was 
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implanted at the injection site of myotoxin and actuated with an external permanent magnet. 
Decreased fibrosis and increased oxygen perfusion was reported in the muscle treated with the 
biphasic ferrogel scaffold.(Cezar et al., 2016) Although the study did not make comparisons to 
normal muscle, the authors did report a two fold increase in contractile force when compared to 
injured muscle that did not receive any therapeutic interventions.(Cezar et al., 2016) This study 
was not performed in a VML model, however, cyclic mechanical compression through a 
biphasic ferrogel scaffold could potentially be used to decrease fibrosis and improve regeneration 
in animal models for VML 
 
Whole muscle replacement and scaling up 
 Currently, most animal models used for VML repair investigations are rodents. While 
animal models are a necessary tool for preclinical investigations, in certain instances size 
differences can outweigh any physiological similarities when studying a small animal model. 
VML is typically presented as an injury where 20% of the muscles volume is absent after 
trauma. A 20% reduction in the TA of a rat will result in a loss of mass of ~100mg and a volume 
less than 0.5 cm3. Large defects in the skeletal muscle of humans could be >200cm3 depending 
on the affected muscle. This difference in scale matters as the diffusion of oxygen into a scaffold 
immediately after implantation can sustain a greater proportion of the cells in a rodent model 
than in a human patient.  
A very recent study by Ward et al. demonstrated that autologous MM could provide 
significant functional recovery in a porcine VML model.(Ward et al., 2016) By creating a 3cm x 
3cm x 1.5cm defect in the peroneous tertius, they reduced the maximum tetanic force by 43%. In 
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muscles repaired with autologous MM, the PT only suffered a 27% reduction in peak tetanic 
contractile force, which represents a 35% increase over the nonrepaired muscles. The recovery in 
the larger porcine model was diminished from the recovery observed in rat VML models, where 
force recovery is generally around 80-85%.(Corona et al., 2013b; Merritt et al., 2010) Ward et al. 
attributed this difference to the size discrepancy between the defect size in the two animal 
models. They also observed an increased inflammatory and fibrotic response in the porcine 
model which hindered revascularization and axonal regeneration. Further studies using larger 
animal models and more specifically, larger defect sizes will accelerate the development of 
effective therapies and strategies for treating VML. 
 The two clinical studies currently published do provide evidence for use of porcine SIS or 
UBM in VML repair, but there needs to be a more systemic approach when there are multiple 
injury sites and various comorbidities that complicate results observed in these initial studies.(J. 
Dziki et al., 2016; Sicari et al., 2014) Skeletal muscle tissue engineering still has several specific 
challenges that will have to be addressed before a new standard of care emerges for the treatment 
of VML.   
 
 
F. Remaining Challenges 
 
Vascularization 
One of the biggest challenges for any translational tissue engineering application to 
overcome, especially scaffold-based therapies, is the challenge of vascularization. Scaffolds by 
their nature have material that separates one portion of damaged tissue from another portion. 
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Scaffolds used to repair VML and regenerate skeletal muscle have seemingly opposing design 
requirements in that one requirement the scaffold should occupy the space left by the volumetric 
defect and the other is that it allow for in the infiltration of host inflammatory and myogenic cells 
into all points within the defect void.  
Engineered skeletal muscle constructs offer an alternative approach to the use of 
scaffolds, but the scale of the current generation of engineered muscle constructs is too small to 
have an application in VML repair.(Juhas, Ye, & Bursac, 2016; Juhas, Engelmayr, Fontanella, 
Palmer, & Bursac, 2014; VanDusen, Syverud, Williams, Lee, & Larkin, 2014b; Williams, 
Kostrominova, Arruda, & Larkin, 2013) Although the Larkin group has used engineered 
constructs to repair VML in animal models, the defect sizes are thus far not clinically 
relevant.(VanDusen et al., 2014b; Williams et al., 2013) In order to serve as a new standard for 
the treatment of VML, engineered constructs would have to have sufficient vasculature with 
functional capillary beds before implantation and would need to have relatively large arteries and 
veins to connect to systemic circulation of the host. This is in addition to scaling engineered 
constructs up to a volume sufficient to repair or even replace whole muscle which has suffered a 
VML injury. However, engineered skeletal muscle has other important applications in 
biomedical research, including as in vitro models for pharmacological investigations and 
diseased tissue surrogates.(Juhas et al., 2016) 
Fibrosis vs. Myogenesis 
 The final challenge to be discussed in this dissertation is specific to skeletal muscle tissue 
engineering. The advancement of the field should be focused on: (1) understanding the response 
of the host immune and muscle tissue to direct cellular activity to myogenesis or fibrosis and (2) 
how to manipulate scaffold based therapies to maximize the myogenic and regenerative response 
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of the host tissue. As discussed previously, further characterization of DSM and MM along with 
characterization of the in vivo response to a combined construct in a VML injury niche will be 
key to developing an effective therapy that is ready for clinical study. Although fibrotic repair 
can provide some functional benefit, therapeutic success should be defined as maximizing 
myogenesis for permanent 100% contractile force recovery. In order to successfully repair and 
regenerate skeletal muscle after a VML injury, researchers should have a clear understanding of 
the differences between innate muscle repair for minor injuries and attempts at self-repair by 
muscle after it has suffered a VML injury. The cellular, biochemical, and mechanical cues that 
are unique to VML injuries should be elucidated to direct researcher toward developing therapies 
that induce a robust myogenic response.  
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